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Abstract 
The main topic of this doctoral dissertation is the biophysical characterization of 
caveolin-1. Caveolin-1 is an integral membrane protein that has been shown to be 
essential for the formation of caveolae.  Caveolae are 50-100 nm invaginations in the 
plasma membrane that have a plethora of cellular functions including signal transduction, 
relieving mechano-stresses on the cell, and endocytosis. Caveolin-1 is at the center of all 
of the functions of caveolae and has been shown to play a predominant role in disease 
states.  However, while there are a large number of biological studies on caveolin-1, there 
are few biophysical studies, leading to a lack of understanding of the structure, topology 
and oligomerization of caveolin-1.  The progress made in these three main areas of 
caveolin-1 research as well as introducing a novel in vitro functional assay for caveolin-1 
and a broadly applicable membrane protein isolation technique are introduced. In chapter 
1, background and general information about caveolin-1 and the biophysical techniques 
that were utilized for its characterization are discussed. Chapter 2 discusses the structural 
characterization of a caveolin-1 construct containing residues 62-136 using NMR 
spectroscopy revealing that the N-terminal residues (62-85) were dynamic and caveolin-1 
contains a helix-break-helix motif with two approximately equal length helices.  Chapter 
3 discusses the structural characterization of caveolin-1 residues (62-178) using NMR 
spectroscopy. Caveolin-1(62-178) is the longest construct of caveolin-1 to be structurally 
characterized and encompasses the previously uncharacterized C-terminal domain which 
formed a long helix. Additionally, caveolin-1 contains a helix-break-helix-break-helix 
motif.  In chapter 4, alanine and phenylalanine scanning mutagenesis of caveolin-1 82-
136, was utilized to identify key structural residues within both helix-1 and helix-2.  In 
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chapter 5, the efforts to establish an in vitro functional assay for caveolin-1 utilizing the 
inhibition of endothelial nitric oxide synthase is presented.  In chapter 6, cysteine 
scanning mutagenesis was utilized to evaluate the exposure of single residues in the 
caveolin-1 scaffolding domain to determine the topology of caveolin-1.  Additionally, an 
evaluation of several different maleimide probes is presented.  In chapter 7, a novel 
method to measure membrane protein oligomerization utilizing homo-FRET in liposomes 
is presented.  Finally, in chapter 8 a purification method utilizing perfluorooctanoic acid 
(PFOA) to solubilize inclusion bodies is presented.  This method has a three-fold 
advantage over conventional solubilization methods because: 1) PFOA can completely 
solubilize inclusion bodies, 2) PFOA is compatible with Ni-NTA chromatography and 3) 
PFOA is easily removed by detergent dialysis.  Overall, this work represents significant 
advancements in understanding of the caveolin-1 protein.  
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Chapter 1: Caveolae, caveolin-1 and biophysical characterization of 
membrane proteins 
 
Caveolae 
The plasma membrane is a complex barrier which separates the interior of the cell 
from the extracellular environment.  It is responsible for several vital biological functions 
such as the movement of molecules in and out of the cell.  The membrane is composed of 
a variety of lipids and has been shown to contain 50% (w/w) protein (1).  These proteins 
are called membrane proteins and are defined by their highly insoluble domains that 
interact with the membrane and participate in many of the functions that occur at the cell 
surface.  These functions include transport of molecules across the membrane, cell-cell 
signaling, and enzymatic reactions (2).  The fluid mosaic model was the original 
hypothesis of how the membrane was organized.  The Fluid mosaic model states that the 
molecules in the plasma membrane diffuse freely in the membrane (3).  However, over 
that last several decades several considerations have been taken into account that call into 
question the validity of this model.  One major aspect is the high density of membrane 
proteins that cause a significant amount of crowding at the membrane surface which 
would hinder the free diffusion of molecules (4).  In recent years,  lipid segregation into 
distinct domains designated as lipid rafts has been observed.  These “raft-like” domains 
are defined by their unique composition compared to the bulk plasma membrane and are 
often more rigid with higher concentrations of cholesterol and sphingomyelin (5). 
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While the existence of these rafts and their prevalence in vivo has been called into 
question, one well defined “raft-like” domain is called caveolae.  Caveolae were first 
identified using electron microscopy in the 1950’s (6).  Caveolae are 50-100 nm 
invaginations within the plasma membrane that play a multifaceted role in cellular 
function.  Most notably, they are involved in: mechano-protection, recruiting and 
concentrating signaling molecules, and endocytosis (7, 8, 9) (Figure 1-1). When there is 
pressure exerted on the membrane, it has been shown that caveolae will begin to flatten 
and increase the surface area of the cell, relieving the pressure to avoid cell lysis (10).  
When the pressure is removed caveolae reform at the cell surface.  Caveolae have been 
shown to undergo non-clatharin dependent endocytosis. The highly curved nature of 
caveolae  
facilitate vesicle formation and transport cargo across the cell (11).  Finally, signaling 
molecules have been found at high levels within caveolae  (12).  Caveolae have been 
observed in several differentiated cell types but are found most predominantly in 
adipocytes and endothelial cells (13, 14).  The loss of caveolae on the cell surface has 
been observed in several disease phenotypes such has heart disease, cancer, and muscular 
dystrophy and is often an indication of cellular dysfunction (15).   
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Figure 1-1. A TEM image of a single caveolae. B) An image of the membrane surface 
showing a number of caveolae. (8, 16). 
 
Cavoelae are enriched in cholesterol, sphingomyelin and an integral membrane 
protein called caveolin (17, 18) (Figure 1-2).  The concentration of cholesterol within 
caveolae is found to be twice that of the bulk plasma membrane (8).  The role of 
cholesterol in these microdomains has not been definitively characterized however the 
rigidity of cholesterol may stabilize the highly curved nature of caveolae.  The role of 
cholesterol in caveolae stabilization is supported by a recent study  of cells treated with 
cholesterol depleting drugs, which had significant changes in caveolae morphology (19).  
It is important to note that caveolae can be formed in E. coli cells, however, these 
domains are unique from those observed in mammalian cells (20). This was an 
unexpected finding because bacteria lack the necessary machinery to perform post-
translational modifications such as palmitoylation and additionally are devoid of 
cholesterol.  therefore, the role of cholesterol in caveolae formation is unclear, and further 
investigation is needed to elucidate the true effects of cholesterol on caveolae.  
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Sphingomyelin is also found to be enriched in caveolae, however recently the extent of 
this enrichment has been called into question (21, 22).   
 
Figure 1-2. Cartoon representation of caveolae composition highlighting the enrichment 
of caveolin-1 and cholesterol (18).  
 
Caveolin has been identified as the major protein component of caveolae.  When 
the caveolin gene is silenced there is a complete loss of caveolae at the plasma 
membrane.  Therefore caveolin is essential for the formation of caveolae. However, the 
cavin family of proteins that are also found in caveolae (23). There are four isoforms of 
cavin (cavin-1, -2, -3, -4) that have been shown to be targeted to the plasma membrane in 
the presence of cavolin-1 (23).  The expression of cavin has been shown to have an effect 
on caveolae formation and morphology.  Additionally, the cavin family has been shown 
to regulate several caveolae functions such as endocytosis (24). While there is evidence 
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that caveolin-1 and cavin interact at the plasma membrane, little is known about the 
formation of these complexes.  It is therefore unclear what factors truly play a role in the 
formation and stabilization of caveolae. What is clear is that caveolin-1 is vital to normal 
caveolae formation and function.  
 
Caveolin 
 There are three isoforms of the caveolin protein (-1, -2, and -3) with caveolin-1 
being the most ubiquitous being found in most cell types (18) (Figure 1-3). Importantly, 
caveolin-1 has been shown to be essential for the formation of caveolae (25).  All three 
proteins have significant sequence similarity both within the isoforms and also across 
species.  Because of  the high degree of conservation, the caveolin protein is crucial for 
cellular function.   Often the functions of caveolin-1 are also applied to the other 
isoforms.  However there are several stark differences within the isoforms that make it 
unlikely that these three proteins have similar structure and function.  Of the three, 
caveolin-1 is the most ubiquitous, and is found in most terminally differentiated cell 
types, for example in adipocytes (13).  Caveolin-2 is often co-expressed with caveolin-1 
and it is thought that caveolin-1 and caveolin-2 form a hetero-oligomeric complex (26).  
It has been shown that when the expression of caveolin-1 is down regulated, caveolin-2 
does not traffic to the membrane and is retained in the golgi (27).   Therefore, caveolin-2 
is unable to form caveolae in the absence of caveolin-1 (28).  Caveolin-3 is expressed 
exclusively in muscles cells and has been shown to be related to muscular dystrophy and 
heart disease.  Caveolin-3 is able to form caveolae in the absence of caveolin-1 (29, 30).  
The functional differences show that while there is significant sequence similarity 
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between the three isoforms, there may be structural differences that govern their overall 
function and distribution.  In particular it should be noted that caveolin-1 contains only 3 
C-terminal cysteines (C133, C143 and C156), which have been shown to be 
palmitoylated in vivo (31). Caveolin-2 and caveolin-3 contain 5 and 9 cysteine residues 
respectively (highlighted in Figure 1-3).  It has been shown that caveolin-2 and caveolin-
3 are palmitoylated, however there has not been an extensive study to show at which 
cysteines or if the palmitoylation has any effect on function (31).  These major 
differences in expression and post translation modifications highlight the need for unique 
studies on caveolin-2 and caveolin-3 that explore their structure and function outside of 
the context of caveolin-1.  
 
 
Figure 1-3. Sequence alignment of the three isoforms of caveolin-1. The cysteine residues 
are underlined to highlight differences in the sequence. The different domains are also 
highlighted to show where they start and stop in each of the isoforms.  
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Caveolin-1 is a 22 kDa protein that was first identified in 1992 by two separate 
groups.  Initially the protein was labeled by one group as VIP21 and the other as caveolin 
(32, 33). Eventually, it was discovered that VIP21 and caveolin were in fact the same 
protein, with the consensus name being caveolin-1 (34).  When the caveolin-1 gene is 
silenced it has been shown that caveolae completely disappear from the cell surface 
indicating that caveolin-1 is essential for the formation of caveolae (25) (Figure 1-4).   
 
 
Figure 1-4. Left panel: lung tissue from mice that are expressing caveolin-1. Black 
arrows highlight caveolae. Right panel: lung tissue from mice with caveolin-1 gene 
silenced (25).  
 
Caveolin-1 has been shown to be intimately related to several functions of 
caveolae (35).  For example, caveolin-1 has been shown to regulate the endocytosis of 
molecules through caveolae.  Caveolae endocytosis is markedly decreased in the presence 
of high levels of caveolin-1. therefore caveolin-1 is a negative regulator of caveolae 
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endocytosis (36).  Caveolin-1 has been shown to interact both directly and indirectly with 
an array of signaling molecules such as endothelial nitric oxide synthase (eNOS), G-
proteins, and Src-like kinases (35, 37, 38). Initially, these molecules were proposed to 
interact with caveolin-1 through a caveolin binding domain (CBM) (ΦXΦXXXXΦ, 
where Φ is an aromatic amino acid) (39).  The role of this motif has been challenged in 
recent structural studies of several of the proposed caveolin-1 binding partners showed 
that many of the CBM domains were buried in the core of the protein structure (40, 41).  
While many of the interactions have been called into question, one established interaction 
has been identified between caveolin-1 and eNOS.  Caveolin-1 has been shown to inhibit 
eNOS activity in vivo and in vitro (37). When the caveolin-1 gene is silenced or a 
frameshift mutation is present in the C-terminal domain, there is a buildup of nitric oxide 
within endothelial cells that leads to disease-type phenotypes (42).   
When caveolin-1 is isolated using detergents such as triton X-114 it has been 
found in large oligomeric complexes (200, 400, and 600 kDa).  Therefore the accepted 
hypothesis is that caveolin-1 oligomerizes in vivo (43). These large oligomeric complexes 
are thought to stabilize the highly curved nature of caveolae by forming a scaffold which 
inserts into the plasma membrane.  However, in vitro reconstitution into both detergent 
micelles and bilayers have shown that caveolin-1 is monomeric (44)and unpublished 
results).  The true oligomeric state of caveolin-1 in vivo is unclear.  The use of mild 
detergents to extract caveolin-1 complexes may induce non-native oligomerization due to 
the highly insoluble nature of caveolin-1.  Additionally, it is difficult to isolate what is the 
main factor in oligomer formation.  For example, cholesterol has been shown to interact 
with caveolin-1 and is enriched in caveolae and could therefore play an important role in 
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the formation and stability of caveolin-1 oligomers (45).  However, there is no conclusive 
evidence to support a role of cholesterol in caveolin-1 oligomer formation. The 
oligomeric state of caveolin-1 and what drives the formation of these complexes is still 
very much under investigation in the scientific community.  
The misregulation and mutation of the caveolin-1 protein has been implicated in a 
large number of diseases such as heart disease and breast cancer (46, 47).  However,  the 
direct effect of caveolin-1 in disease states is not clearly understood.  For example, the 
loss of caveolin-1 expression has been shown to lead to an increase in tumor proliferation 
and metastasis in several types of cancer (48).  Uniquely, in prostate cancer it has been 
found that caveolin-1 is over-expressed and that the silencing of the caveolin-1 gene 
actually has positive effect in slowing prostate cancer progression (49). Therefore, the 
role of caveolin-1 in cancer progression seems to be cell type specific.  A point mutation 
in the caveolin-1 C-terminal domain (Proline 132 to Leucine) has also been identified in 
patients with breast cancer and is thought to cause an increase in metastasis (50).  
However, while it was initially reported that 16% of patients possess the P132L mutation, 
recent studies have called the prevalence of P132L into question (51, 52).  The ambiguity 
of the role of caveolin-1 in breast cancer is an example of the lack of understanding of 
how caveolin-1 functions in vivo and the true effects of its misregulation. To fully 
understand and appreciate how caveolin-1 participates in cellular disease it is necessary 
to have a detailed understanding of the protein on a molecular level. 
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Caveolin-1 Structure 
The first structural characterization of caveolin-1 was based on primary sequence 
analysis (53). It was found that caveolin-1 contains a large hydrophobic domain (33 
amino acids), that is too long to span the bilayer once, but is too short to span the bilayer 
twice (Figure 1-5).  The lack of soluble residues means that any loop/turn would have to 
reside in the membrane.  To establish which side of the plasma membrane the N- and C-
termini reside, glycosylation, biotinylation and immunofluorescence studies were 
employed (43, 54, 55).  Based on these studies caveolin-1 is predicted to have an unusual 
topology with the protein forming a turn within the hydrophobic core of the membrane 
that results in both the N- and C- termini facing the cytosol with no portion of the 
polypeptide entering the extracellular space (43).  However, this would place unsatisfied 
hydrogen bonds within the water depleted membrane.  But recent molecular simulations 
studies along with fluorescence experiments agree with the placement of the turn within 
the membrane (56).   
 
13 
 
 
Figure 1-5. Hydropathy plot of caveolin-1.  Residues in red are the hydrophobic domain.  
 
 Caveolin-1 is traditionally represented by four domains that are based on primary 
sequence analysis: the N-terminal domain (residues 1-81), the scaffolding domain 
(residues 82-101), the intra-membrane domain (residues 102-134), and the C-terminal 
domain (residues 135-178) (53) (Figure 1-6). Initially, structural studies were carried out 
on individual caveolin-1 domains.  The limitation to use only short peptides was largely 
due to the difficulty of purification and solubility of full length caveolin-1.  
 
 
 
96 137 
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Figure 1-6. Cartoon illustrating the domains of caveolin-1.  The residues within each 
domain are indicated. The proposed break region is indicated by “GIP”.   
 
A caveolin construct containing only the N-terminal domain (residues 1-81) has 
been shown to be unstructured in an aqueous environment (57).  This domain is the most 
variable between the isoforms of the caveolin family and it has been shown that the 
removal of the first 61 amino acids has no effect on the trafficking of caveolin-1 or the 
formation of caveolae (58). However, it has been implicated in several interactions of the 
caveolin-1 protein such as cholesterol recruitment (59).  Additionally, the N-terminal 
domain has been shown to be phosphorylated which may be critical for caveolin-1 
function (60).  There are two forms of caveolin-1 that are found in vivo, caveolin-1α and 
caveolin-1β.  The two forms are identical with the exception that caveolin-1β is lacking 
the first 31 amino acid residues and begins at methionine 32 (61).  
The next domain has been designated the scaffolding domain (residues 82-101). 
The scaffolding domain appears to be important for binding signaling molecules such as 
endothelial nitric oxide synthase, along with oligomerization and cholesterol binding 
(35).  Initially, based on primary sequence analysis it was predicted that the scaffolding 
domain was a short amphipathic helix which rested on the surface of the membrane (53). 
The scaffolding domain was found to be unstructured in DPC micelles using NMR 
spectroscopy. The addition of a small portion of the intramembrane domain increased the 
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helical character of the scaffolding domain (62).  However, another study utilizing solid 
state NMR spectroscopy showed that in the presence of cholesterol  a similar construct 
contained beta sheet characteristic (63).  The final characterization of the scaffolding 
domain showed that in the presence of the full intramembrane domain a portion of the 
scaffolding domain contained both unstructured and helical residues (residues 82-86 are 
unstructured and residues 87-101 are helical). Importantly, the helix continues from the 
scaffolding domain into the intramembrane domain (56). The contrast in these studies 
could be attributed to the presence of cholesterol in the Hoop et. al. experiments however; 
it is difficult to make absolute assumptions without the full protein being present (63). 
 The intramembrane domain has been postulated to be critical for the formation of 
caveolae and is the most conserved region between all of the caveolin-1 isoforms (Figure 
1-2). Initially, based on primary sequence analysis, the intramembrane domain was 
predicted to contain two helices separated by a short four residue break (residues 108-
111) (53).  Recent structural studies using NMR have examined the secondary structure 
of the intramembrane domain and revealed that this domain contains a helix-break-helix 
motif which is consistent with the proposed U-shaped topology of caveolin-1 (64).  The 
break region was also confirmed utilizing site directed mutagenesis although it was 
shown to include only three residues 108, 109 and 110.  This break is hypothesized to be 
the location of the intramembrane turn (64).  The insertion of the two helices into the 
bilayer can be thought of as a “wedge” which will asymmetrically separate lipid 
molecules in the bilayer causing the curvature found in caveolae (Figure 1-7).   
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Figure 1-7. Cartoon representation of caveolin-1 insertions into the bilayer.  
 
The C-terminal domain has been the most under-studied domain of the caveolin-1 
protein.  The previous structural studies were performed on truncated constructs that do 
not contain the C-terminal domain.  The C-terminal domain is predicted to be an 
amphipathic helix that rests on the surface of the membrane (53).  The location of the C-
terminal helix at the membrane surface is supported by the presence of three cysteine 
residues within the C-terminal domain which have been shown to be palmitoylated in 
vivo (31).  Additionally the C-terminal domain has been implicated in several functions 
of caveolin-1. The C-terminal domain has been shown to be important for caveolin-1 
trafficking to the membrane and formation of the large oligomeric complexes that are 
thought to stabilize caveolae(58, 65, 66).  Additionally, many caveolin-1 binding partners 
such as endothelial nitric oxide synthase, connexin, and Retrovirus NSP4, also interact 
directly with the C-terminal domain making it an important binding region within 
caveolin-1 (37, 67, 68).  Recent studies have identified a frameshift mutation within the 
C-terminal domain that is found in patients with familial pulmonary arterial hypertension 
and a patient with idiopathic pulmonary hypertension (69, 70).  It is clear that the C-
terminal domain is intimately involved in caveolin-1 function and needs to be structurally 
characterized to fully elucidate its role.  
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The structure of caveolin-1 is an on-going and important question that needs to be 
answered to fully understand how this protein functions within the cell.  One of the goals 
of the following chapters is to present new work that has contributed to the structural 
determination of caveolin-1.  
 
Biophysical Characterization of Membrane proteins 
About 30% of proteins encoded in the genome are membrane proteins (71).  
However, the majority of solved protein structures consist of soluble proteins (72).  The 
lack of structural data is because of the unique challenges that membrane proteins present 
not only for structure determination but also for functional characterization.  Membrane 
protein expression and purification has been a major challenge in the structural 
characterization of membrane proteins because of the large amounts of protein that are 
needed to utilize conventional techniques such as X-ray crystallography.  The low protein 
production is due to the toxicity of membrane proteins when they are over-expressed in 
expression systems such as E. coli and the relative low level of native expression in 
mammalian cells (73). Therefore, the majority of membrane protein structures that have 
been solved are extremely stable helical bundles or beta-barrels which can be expressed 
and purified at high levels (74).  While these proteins have advanced several structural 
techniques, less stable membrane proteins that have unique motifs have not been 
explored.  Chapter 8 in this dissertation presents work on the purification of highly 
insoluble membrane proteins for structural determination.  
Another major challenge in the biophysical characterization of membrane proteins 
is the need for a suitable membrane mimetic to solubilize the protein.  The presence of 
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these mimetics can cause significant challenges when utilizing traditional techniques 
because the mimetic alters the size of the protein-lipid complex and also most 
lipids/detergents are not compatible with these techniques.  For example, X-ray 
crystallography has gained popularity as the gold standard of structural determination.  
There is a significant challenge when trying to apply X-ray crystallography to membrane 
proteins because most lipids and detergents will affect crystal formation (75).  It is 
however essential to keep these molecules around in order to prevent the membrane 
proteins from aggregating or falling out of solution.  Additionally, the crystalline lattice 
that is formed by some detergents may make it impossible to glean intermediate or fluid 
information about the protein structure that may be present in the fluid membrane.  The 
presence of lipids has also been shown to have a major effect on membrane protein 
structure and proteins can have different specificity for lipid environments (76).  There 
are three main membrane mimetics that are commonly used in membrane protein 
characterization: micelles, bicelles and vesicles (Figure 1-8).  Each of these mimetics 
contains their own advantages, but not all are compatible with all techniques. 
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Figure 1-8 Illustrations of A) Micelle, B) bicelle, and C) vesicle  
 
Micelles 
Micelles are detergent aggregates which contain a water depleted core and a polar 
surface.  Most often, they are represented as spherical aggregates however studies have 
shown that the shape of the aggregates depends greatly on the characteristics of the 
detergent (77). Micelles are small and dynamic with a constant flux between aggregate 
and monomer. The critical micelle concentration (CMC) is the minimum amount of 
detergent required to form aggregates.  Micelles are an attractive membrane mimetic and 
have been utilized in membrane protein structure determination by solution state NMR 
and also to lesser extent X-ray crystallography (77, 78). It has been shown that most 
membrane proteins can maintain their secondary structure in micelles and also that there 
are very few changes between structures determined in bilayer mimetics and micelles 
(79). However, micelles have the disadvantage that they are not a true bilayer and cannot 
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handle the introduction of physiological levels of molecules such as cholesterol (which 
can be important in the case of raft associated proteins).  Additionally, micelles are small 
and highly curved which can introduce artifacts in membrane protein structure 
determination (80).  
 
Bicelles 
Bicelles are discoidal lipid/detergent aggregates that have been shown to have 
several advantages over micelles and are still compatible with several biophysical 
techniques such as NMR spectroscopy (81).  Bicelles are formed by mixing a long chain 
phospholipid with a short chain phospholipid or detergent molecules. One common 
system is bicelles composed of DMPC (long chain) and DHPC (short chain). The long 
chain phospholipid forms a long planar region and the short chain molecules form a rim 
that protects the hydrophobic core of the long chain lipid form the solution (82, 83).  
Bicelles have an advantage because the short chain detergent molecules are in flux which 
makes these structures dynamic (84). The size and other properties of bicelles are 
governed by the molar ratio of the long chain lipid to the short chain detergent designated 
as q. It is possible to tune the size of the planar region by adjusting the molar ratio to give 
a larger q.  Additionally, it has been shown that bicelles can be formed with lipid 
molecules of various chain lengths making the overall thickness tunable.  This tunability 
allows for characterization of membrane proteins in a true bilayer environment under 
more native like conditions.  However, it is not possible to determine membrane protein 
orientation in bicelles, and at lower q values (between 0.1-0.3) the planar region becomes 
very small and there is significant mixing with the rim region (forming a mixed micelle 
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rather than a true bilayer).  The incorporation of large amounts of cholesterol into bicelles 
can also be challenging with the upper limit being ~5%.  Additionally bicelles have been 
used extensively in solid state NMR, though some techniques require large amounts of 
protein which can be difficult to achieve (85).   
 
Vesicles  
Vesicles are hollow aggregates of bilayer forming amphipathic molecules.  
Vesicles that are formed from phospholipids are referred to as liposomes. When 
phospholipids are exposed to an aqueous environment they will spontaneously form 
vesicles.  Liposomes can contain one layer (uni-lamellar) or multiple layers multi-
lamellar).  Liposomes are often characterized by size which can be controlled based on 
preparation.  Unilammelar liposomes can be formed in three sizes small (SUV), medium 
(MUV) and large (LUV).  Often SUVs are unstable and will fuse over time to form 
LUVs.  Liposomes are widely used as drug delivery tools because of their 
biocompatibility (86). Vesicles have several advantages when compared to both bicelles 
and micelles.  Because liposomes contain an aqueous interior it is possible to determine 
the orientation of a protein in the bilayer.  Additionally,  vesicles allow high levels of 
incorporation of cholesterol which can be used to determine how cholesterol affects a 
proteins behavior.  However, vesicles cannot be utilized in the structural techniques such 
as NMR spectroscopy and X-ray crystallography.  
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Biophysical techniques] 
Circular dichroism spectroscopy 
The most common technique to determine the major secondary structure 
components of a membrane protein is circular dichroism spectroscopy (CD).  Based on 
the differences in how molecules absorb right and left handed polarized light, it is 
possible to assign the overall secondary structure.  A α-helical protein shows a signature 
of a maximum at 190 nm and two distinct minima at 208 and 222 nm. A beta sheet shows 
a minimum at 217 nm.  A random coiled structure shows a minimum at  204 nm (Figure 
1-9) (87).  Additionally, using CD it is possible to determine how changes in the protein 
environment (pH, concentration, or temperature) affect the secondary structure. While 
CD can give an overall picture of the secondary structure of a membrane protein, it 
cannot give residue specific structural information. It is possible to use fitting algorithms 
to determine the percentage of each type of structure, however there can be significant 
bias if there is a large helical content in the protein which can dominate the spectra. It can 
be difficult to acquire quantitative data from a CD spectrum because there can be 
increases in peak intensity based on concentration and also background from helical 
character.  It is known that if a protein contains even a small amount of helical character, 
the spectrum will be overpowered by that signal (88).  The lack of resolution means that 
there is a need for an additional technique to give more atomistic information.  However, 
CD is a powerful tool to quickly determine if a protein is folded or to examine how 
environmental elements affect protein structure.  
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Figure 1-9. Representative spectra for the three major secondary structures of proteins 
(87). 
 
NMR Spectroscopy 
Nuclear magnetic resonance spectroscopy has emerged as a powerful tool to 
elucidate protein structure.  It is especially attractive for the structural determination of 
membrane proteins because of its compatibility with many detergent systems.  therefore 
membrane protein structure can be determined in solution (89).  Nuclear magnetic 
resonance has the advantage that it can give residue specific structural information based 
on chemical shift.  Using isotopically labeled proteins it is possible to elucidate the 
secondary and tertiary structure of the protein.  Protein NMR relies on samples that are 
enriched in isotopically labeled atoms such as 15N and 13C.  There have been several 
advancements in the expression and purification of isotopically labeled protein samples 
that are suitable for NMR experiments (90).  
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Structural determination utilizing solution state NMR requires several consecutive 
experiments that are compiled to elucidate the overall secondary structure.  The initial 
experiment is called heteronuclear single quantum correlation (HSQC).  The chemical 
shifts in a two dimensional NMR spectrum (HSQC) arises from the transfer of 
magnetism from the backbone nitrogen and amide proton.  This is often the first 
experiment to determine the optimal detergent system for further NMR experiments.  A 
well dispersed spectrum indicates that all of the amino acids are experiencing a unique 
environment and therefore the protein is well structured under the current conditions.  It 
can also be utilized for monitoring structural changes introduced by the addition of point 
mutations.  
After a high quality HSQC is obtained, three dimensional  NMR experiments 
(HNCA, HNCACB, and HNCO), can be performed to give the chemical shifts of the Cα 
carbon, Cβ carbon and carbonyl carbon.  However, when utilizing NMR for membrane 
protein structure determination, there is a significant amount of spectral overlap.  The 
high degree of overlap can make peak assignment challenging.  It is therefore necessary 
to utilize specific amino acid labeling to help identify peaks within the NMR spectra.  In 
this technique only a single amino acid in the protein sequence (for example alanine) is 
isotopically labeled.  Specific amino acid labeling can aid significantly in assigning 
backbone chemical shifts.  After all the chemical shifts have been assigned it is possible 
to predict the secondary structure of the protein backbone.  
 
 
 
25 
 
Homo-FRET 
 A common biophysical technique to determine protein-protein interactions is 
Förster resonance energy transfer (FRET).  This technique utilizes two fluorophores that 
have overlapping excitation and emission spectra.  When one fluorophore is excited 
(designated as the donor), energy is transferred to the second fluorophore (designated as 
the acceptor). This energy transfer can only occur when the donor labeled molecule and 
the acceptor labeled molecule are in close proximity (91) .  While FRET experiments can 
give valuable information about what proteins belong to a complex, it lacks the ability to 
distinguish oligomeric states between the same molecules. For example, if the same 
protein forms a homo-oligomeric complex, FRET will be observed. However, there is no 
way to glean the number of monomers that are contained within the complex.   
Homo-FRET is a process in which a single fluorophore transfers emission energy 
with itself upon excitation.  Therefore, homo-FRET is most pronounced in fluorophores 
with a small Stokes shift.  Advantageously, homo-FRET can be used to determine the 
oligomeric state of membrane proteins by measuring changes in steady-state anisotropy 
as a function of the degree in which the population of subunits are labeled with a 
fluorophore (92).  If the identical fluorophores are part of an oligomeric complex, they 
will reside in close proximity to each other, and thus be able to participate in energy 
transfer.  However, during the energy transfer process, polarization is lost, and the degree 
of polarization loss can be used to determine the order (e.g. dimers vs. trimers) of the 
complex (93).  Practically, various degrees of subunit labeling can be achieved by 
mixing, in appropriate ratios, solutions of labeled and unlabeled membrane protein, and 
plotting the anisotropy as a function of fractional labeling.  Normally, homo-FRET is 
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measured by photobleaching of the fluorophore (to generate the dark sample) and 
measuring the change in the anisotropy at different ratios of non-photobleached 
fluorophore (considered the light sample) (92, 94).  Chapter 6, discusses the efforts to 
utilize point mutations that render a “dark” fluorophore that is compatible with homo-
FRET.  
All of these techniques are powerful tools for the biophysical characterization of 
membrane proteins.  However, because caveolin-1 is a unique protein, there is added 
complexity when utilizing each technique.  Therefore, not only is the use of these 
techniques being discussed in this dissertation but also several novel approaches to these 
techniques are presented.  
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Chapter2. Structural characterization of Caveolin-1(62-136).  
Abstract 
  Previous structural studies of caveolin-1 have been conducted on each domain 
separately.  While these studies have given important initial insights, because of the 
unique topology of caveolin-1 it is necessary to analyze the domains in the context of one 
another. Additionally, caveolin-1 has been implicated in several biological functions but 
without structural context it is not possible to determine mechanistically how the protein 
affects cellular biology.  To begin to garner a more complete structural picture of 
caveolin-1 a construct containing residues 62-136 was analyzed in LMPG micelles 
utilizing NMR spectroscopy. This construct contains the intact scaffolding and 
intramembrane domains as well as a portion of the N-terminal domain which has not 
been previously characterized in the context of the other two domains.  This study 
revealed that caveolin-1 contains a helix-break helix motif with Helix-1 containing 
residues 89-107 and Helix-2 containing residues 111-128. The remaining residues were 
found to be unstructured. This is the first study to indicate that the N-terminal domain is 
unstructured in the presence of the scaffolding and intramembrane domain.  Additionally, 
the study  shows that the addition of N-terminal residues, does not affect the length of 
Helix-1.  
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Introduction. 
Previous studies conducted on the intramembrane domain identified three key 
residues (108, 109, and 110) that are proposed to be the location of the helix break (turn) 
that facilitates return of the C-terminus to the cytoplasmic face of the plasma membrane.  
This study was the first reported evidence of the Helix-break-Helix motif (64). However, 
this study examined only the transmembrane domain and a portion of the scaffolding 
domain (residues 96-136).  Interestingly, the first helix was shown to start at the 
beginning of the construct indicating that a construct with additional N-terminal residues 
may show a continuation of the helix.  To explore further where the first transmembrane 
helix begins, the truncated construct was expanded to include residues 82-136 which 
encompasses the scaffolding domain. Through secondary structure analysis it was 
revealed that the first helix actually begins at A87 (56). This indicates that the previously 
termed “scaffolding domain” is actually part of helix-1 and there is no break in the helix 
to separate these regions as was proposed by previous models (53).    
While both of these previous studies gave vital information on the scaffolding and 
intramembrane domains, they lacked any portion of the N-terminal domain.  The N-
terminal domain has been shown to be the most variable among the three isoforms of 
caveolin (See Figure 1-3). Caveolin-1 has the longest N-terminal region followed by 
caveolin-2 and -3 respectively. Studies examining the role of the different caveolin-1 
domains have shown that a deletion construct lacking the first 61 amino acids, has been 
shown to be functional (58). However, while the N-terminal domain does not play a role 
in the formation of caveolae, it has been shown to perform several other roles such as 
cholesterol binding and also several sites of phosphorylation have been identified.   
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 To elucidate the effect of N-terminal residues on the previously reported helix-
break-helix motif, an additional 20 amino acids were appended to the previously studied 
construct caveolin-1 (82-136). This construct, caveolin-1(62-136), contains the intact 
scaffolding and transmembrane domains and the portion of the N-terminal domain that 
has been shown to be important for the formation of caveolae.  Using NMR spectroscopy 
the secondary structure of caveolin-1(62-136) was determined. Three dimensional NMR 
experiments and specific labeling protocols were performed to assist in the secondary 
structure assignment of this region.  
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Materials and Methods 
Expression of isotopically labeled samples for NMR spectroscopy 
Caveolin-1(62-136)_M111L_C133S (caveolin-1(62-136)) was expressed as a 
TrpLE fusion as described previously (see Appendix 2-1) (95).  Methionine 111 was 
mutated to leucine to prevent off target cleavage.  The mutation of this position is a 
conservative mutation as position 111 is a leucine in both caveolin-2 and caveolin-3.  
Cysteine 133 was mutated to serine to prevent non-biologically relevant disulfide 
bonding.  This mutation has been shown to have no effect on the protein function in vivo 
(31). Briefly, caveolin-1(62-136) was cloned into pet24a and transformed into BL-
21(DE3) cells.  A 5 mL overnight culture was used to inoculate 1L of M9 minimal media 
that was enriched with 15N nitrogen to yield an isotopically labeled sample for NMR (see 
Appendix 2-2). Cultures were grown for 18 hours at 37C and harvested at 5780 xg for 
30 minutes. Cell pellets were them washed with 200 mL of 0.9% (w/v) saline and stored 
at -80C until purification. Similarly, doubly (15N and 13C) and triply (15N, 13C and 2H) 
labeled samples were generated utilizing the optimized protocol of Marley et. al.(96).  
Briefly, 1L LB cultures were grown to an optimal OD600 of 0.8 and harvested at 5000 xg 
for 30 min at 25C.  Cells were washed by resuspension in minimal media containing no 
13C or 15N and pelleted again at 5000 xg for 30 minutes at 25C. The pellets were 
resuspended in minimal media containing 13C and 15N and grown for 2 hours at 37C. 
Protein expression was induced by the addition of 1 mM IPTG and the culture was grown 
for another 8 hours. In the case of the triply labeled samples, the procedure was the same 
except that the water in the media was supplemented by D2O.  Specific labeled samples 
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were generated utilizing M9 minimal media supplemented with 15N amino acid of interest 
(see Appendix 2-3). 
 
Purification 
 All isotopically labeled samples were purified utilizing the previously reported 
method by Diefenderfer et. al. (95). Briefly, cell pellets were resuspended in 200 mL of 
20% sucrose solution and lysed by sonication for 15 minutes.  Inclusion bodies were 
isolated by centrifugation for 2 hours at 27,000 xg at 15C.  Pellets were washed with a 
solution containing 1% triton X-100 to remove any membrane components and sonicated 
for 15 minutes.  The solution was centrifuged for 1 hour at 27,000 xg at 15C.  Pellets 
were resuspended with 80 mL of 1 M Tris pH 8.0 and sonicated for 10 minutes. After 
sonication, 180 mL of isopropyl alcohol was added and the solution was centrifuged at 
27,500 xg for 2 hours.  The supernatant was removed and the inclusion body pellet was 
resuspended in 30 mL of 88% formic acid.  The TrpLE protein was cleaved by addition 
of 0.2 g of cyanogen bromide and reacted for 18 hours. The fusion was separated from 
caveolin-1 utilizing reverse phase HPLC.   
 
Protein reconstitution 
 Based on previous data, LMPG was chosen as the detergent for these studies.  
Please note that extensive detergent screening was performed on this construct with only 
LMPG yielding high quality NMR spectra. In addition, LMPG is a detergent that is 
widely used for membrane protein NMR studies (97, 98, 99, 100). Approximately 1 mM 
of lyophilized protein was reconstituted into 600 μL of 100 mM LMPG, 20 mM Pi pH 
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7.0, 100 mM NaCl and 10% D2O. Samples were vortexed and heated to homogeneity and 
filtered through a 0.2 uM spin filter.  
 
NMR Spectroscopy 
TROSY-HSQC spectrum were acquired for caveolin-1(62-136) on a 600 MHz 
Bruker Advance II spectrometer equipped with a cryoprobe using 256 (15N dimension) x 
2048 (1H dimension) complex points and 64 scans.  Additional 3-dimensional 
experiments (HNCA, HNCACB, HNCO and HN(CO)CA) were also acquired to aid in 
the backbone assignment.  All NMR data was processed utilizing NMRpipe. Dihedral 
angles were obtained utilizing the processing program TALOS+.  
 
Chemical shift indexing (CSI) plot 
The CSI plot is generated by subtracting the reference Cα chemical shift from the 
Cα that was recorded from the spectrum.  If the resulting value is positive it demonstrates 
α-helical structure, if the value is negative it demonstrates β-sheet (101). Importantly, 
when identifying secondary structure, a stretch of either positive or negative values is 
needed.   
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Results and Discussion 
Secondary Structure assignment of Caveolin-1(62-136) 
          Figure 2-1 shows the assigned 2-dimensional 1H-15N TROSY-HSQC spectrum of 
caveolin-1(62-136).  From the TROSY-HSQC it can be seen that the NMR spectrum of 
caveolin-1(62-136) has a significant amount of spectral dispersion indicating that the 
protein is well behaved under the experimental conditions.  Once a high quality HSQC 
spectrum is obtained, giving the nitrogen and amide proton chemical shift, it is necessary 
to determine which amino acid corresponds to which peak. Three-dimensional 
experiments can give the chemical shifts for the Cα carbon (HNCA), C-beta carbon 
(HNCACB), and carbonyl carbon (HNCO and HN(CO)CA).  
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Figure 2-1. Assigned TROSY-HSQC of caveolin-1 (62-136).  
 
Specific amino acid labeling 
Because caveolin-1 is a membrane protein, there is also a significant amount of 
spectral overlap that can make assigning the HSQC difficult.  To aid in the assignment 
specific amino acid labeling can be employed to help elucidate which amino acids 
correspond to a particular peak.  There are several considerations when choosing which 
amino acid to specifically label in order to yield the most effective data.  First, the amino 
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acid should be prevalent in the sequence and also well dispersed.  Examining the 
sequence of caveolin-1(62-136) (see Appendix 2-1), there are several prevalent residues 
that are well dispersed throughout the sequence. For example, there are six valine 
residues that are located throughout the protein sequence.  Once the specific labeled 
spectrum is acquired, it can be overlaid with the WT spectrum to identify which peaks 
correspond (in this case) to valine (Figure 2-2).   
 
Figure 2-2. Overlay of caveolin-1(62-136) (red) and specifically labeled valine caveolin-
1(62-136) (cyan). 
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The second consideration when selecting which amino acid to specifically label is 
the degree of scrambling.  Because several amino acids are used as the template for other 
amino acids during protein expression (i.e. glycine and phenylalanine) they are not ideal 
choices for specific labeling (90).  For example, there are 8 phenylalanine residues in 
caveolin-1(62-136) and therefore only 8 peaks should be on the HSQC.  However, the 
phenylalanine spectrum is showing more than 8 peaks indicating that there is some 
degree of off target isotopic labeling (Figure 2-3).  However, it is still possible to utilize 
the data obtained by comparing with the other spectrum obtained but caution should be 
used.  
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Figure 2-3. Overlay of caveolin-1(62-136) (red) and specifically labeled phenylalanine 
(yellow).  
 
Chemical shift index plot 
The HNCA is the most sensitive of the three dimensional experiments and is often 
the first performed (101). Because the nitrogen is coupled to the Cα carbon on the same 
amino acid and also the α carbon on the previous amino acid, a strong and weak peak are 
observed. The strong peak is associated with the Cα that is directly bonded to the 
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nitrogen and the weak peak is associated with the previous Cα carbon (Cα-1).  This 
allows for assignment of the protein backbone in a stepwise fashion.  Additionally, the 
Cα chemical shifts can give information about the secondary structure of the protein.  
Figure 2-4 shows the chemical shift indexing plot of caveolin-1(62-136).  As can be seen 
within the CSI plot of 62-136, there are two distinct helices that contain a break at 
residues G108, I109, and P110.  Interestingly, the N-terminal residues appear to be 
showing some beta sheet characteristic (stretch of negative values). However, because the 
CSI plot relies only on the C-α chemical shift, it is necessary to refine the structural 
prediction by adding more restraints.  
 
Figure 2-4. The Chemical shift indexing plot of caveolin-1(62-136) 
 
While the HNCA contains a large amount of preliminary information, it can often 
be difficult to assign a full spectrum using only the Cα chemical shift. This is due in large 
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part to significant overlap and peak ambiguity. The HN(CA)CB gives the Cβ chemical 
shift. The HNCO will give the CO chemical shift.  The combination of all of these 
experiments along with the specific amino acid labeling allow for complete backbone 
assignment of the protein.  The chemical shifts obtained can then be utilized to predict the 
overall secondary structure.  
 
Talos+ prediction for caveolin-1(62-136) 
To determine the secondary structure of caveolin-1(62-136) the chemical shifts 
for the HN, N, Cα, Cβ and CO chemical shifts can be entered into TALOS+.  Table 2-1 
shows the TALOS+ output file.  This file indicates the assigned Φ and Ψ angles based on 
the restraints that are entered from the backbone assignments. Φ angles around 
 -60 and Ψ angles around -40 indicate an α-helix.  Clearly, from this data, caveolin-1(62-
136) shows a helix-break-helix motif with Helix-1 containing residues 87-107 followed 
by a three residue break and Helix-2 containing residues 111-128.  Residues 62-86 are 
shown to be dynamic.  When comparing the Talos+ prediction with the CSI plot, there 
are several residues in the N-terminal region with negative ΔCα values which could 
indicate the presence of β structure.  However the N-terminal region is dynamic based on 
the Φ and Ψ angles predicted by Talos+.  Additionally, there is a short segment of helical 
residues within the N-terminal domain (residues 78-81). This single helix turn was 
previously predicted and is thought to aid in membrane attachment (53).   
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Table 2-1. Talos+ data for caveolin-1 (62-163).  
Residue Φ angles Ψ angles Structure Prediction Residue Φ angles Ψ angles
Structure 
Prediction
D ---------- --------- None Y -62.196 -41.304 α-helix
V -117.321 140.184 Dynamic R -62.356 -42.091 α-helix
V -98.852 140.681 Dynamic L -62.048 -44.97 α-helix
K -86.934 135.048 Dynamic L -60.966 -43.951 α-helix
I -115.187 133.807 Dynamic S -64.009 -38.429 α-helix
D -87.828 118.907 Dynamic A -64.347 -42.146 α-helix
F -117.577 140.82 Dynamic L -64.116 -42.612 α-helix
E -98.677 137.93 Dynamic F -87.852 0.537 α-helix
D -93.109 -15.174 Dynamic G 90.559 2.564 unstructured
V -117.85 127.953 Dynamic I -86.158 129.854 unstructured
I -95.148 -16.137 Dynamic P -59.382 140.555 unstructured
A -94.14 161.392 Dynamic L -54.127 -38.561 α-helix
E -83.383 136.48 Dynamic A -60.213 -39.198 α-helix
P -69.411 148.881 Dynamic L -65.687 -41.329 α-helix
E -83.036 131.988 Dynamic I -63.827 -42.572 α-helix
G 77.638 10.305 Dynamic W -67.21 -37.725 α-helix
T -60.375 -40.752 α-helix G -72.463 -40.14 α-helix
H -62.201 -43.477 α-helix I -67.228 -40.026 α-helix
S -69.838 -30.784 α-helix Y -64.836 -40.901 α-helix
F -67.965 -35.879 α-helix F -65.118 -38.802 α-helix
D -79.402 -10.415 Dynamic A -66.815 -39.364 α-helix
G 83.88 16.12 Dynamic I -65.104 -45.313 α-helix
I -67.556 -22.703 Dynamic L -65.843 -42.467 α-helix
W -82.324 -21.343 Dynamic S -68.467 -38.701 α-helix
K -76.72 -23.606 Dynamic F -63.778 -37.488 α-helix
A -67.641 -36.472 α-helix L -60.795 -46.389 α-helix
S -67.436 -36.365 α-helix H -64.893 -41.228 α-helix
F -64.512 -45.214 α-helix I -67.803 27.275 α-helix
T -65.138 -36.406 α-helix W -88.141 -18.04 Dynamic
T -62.98 -40.967 α-helix A -89.369 -9.301 Dynamic
F -76.844 -27.585 α-helix V -106.302 2.888 Dynamic
T -62.563 -41.032 α-helix V -84.904 130.917 Dynamic
V -63.123 -40.627 α-helix P -63.012 145.178 Dynamic
T -66.431 -39.997 α-helix S -87.195 -4.42 Dynamic
K -62.344 -39.45 α-helix I -112.535 -2.614 Dynamic
Y -66.196 -39.699 α-helix K -84.364 116.019 Dynamic
W -62.902 -39.367 α-helix S ---------- ----------- None
F -62.483 -44.139 α-helix
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 Based on the Talos+ data a preliminary model of the secondary structure of 
caveolin-1(62-136) can be determined (Figure 2-5).  From the data presented caveolin-1 
contains a helix-break-helix motif which is in agreement with previous structural 
characterization.  Interestingly the addition of N-terminal residues has no effect on the 
location of the start of Helix-1.  By determining the secondary structure of caveolin-1 
(62-136), a greater understanding the complete structure of caveolin-1is achievable.   
 
 
Figure 2-5. Cartoon model of the secondary structure of caveolin-1(63-136).  
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Conclusions 
 Using solution state NMR spectroscopy the secondary structure of caveolin-1(62-
136) was assigned and it was determined that the protein contains a dynamic N-terminal 
domain and that the scaffolding and intramembrane domains form a helix-break-helix 
motif.  Interestingly, there is a short stretch of helical amino acids in the N-terminal 
domain (about four residues) which can indicate that there is a single helix turn.  This 
finding is in agreement with previous structure predictions that predicted the N-terminal 
domain contains a short helix that is important for membrane attachment.  This is the first 
characterization of the functional portion of the N-terminal domain in the context of the 
scaffolding and intramembrane domain.  The presence of the short helix turn highlights 
that working with larger protein constructs (that contain several protein domains) is vital 
as the previous circular dichroism spectroscopy showed that the N-terminal domain alone 
is unstructured(57).  This also highlights the need to use structural techniques that can 
give structural assignments with greater resolution so that small structural nuances can be 
determined.  
The determination of the secondary structure of caveolin-1 is not only vital for 
understanding the protein function it also  introduces a new class of structural proteins 
whose function is to shape the membrane.  The unique helix-break-helix motif is the key 
to understanding how caveolin-1 works to shape the membrane and form caveolae.  
Additionally, the secondary structure can also help to understand how the protein 
interacts with its proposed binding partners.   
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Appendix 2.1- Sequence for NMR studies 
Caveolin-1(61-
136)_M111L_C133S 
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYWFY  
RLLSALFGIPLALIWGIYFAILSFLHIWAVVPSIKS 
  
  
44 
 
Appendix 2-2.  Recipe for auto-induction media 
MDG starter  
10 μL 1 M MgSO4 
 
1 μL 1000X trace metals 
 
50 μL 25% aspartate  
 
100 μL 50XM 
 
40 μL 40% glucose 
 
4.8 mL sterile water 
 
5 μL 1000X kanamycin 
 
N-5052 
14.196 grams Na2HPO4 
 
13.609 grams KH2HPO4 
 
1.42 grams Na2SO4 
 
1956 mL water 
 
5.45 grams 15NH4Cl 
 
4 mL 1 M MgSO4 
 
400 μL 1000X trace metals 
 
40 mL 50x5052 
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Appendix 2-3. Recipe for specific amino acid labeling media 
1L of M9 media  
778mL of H2O  
 
200mL of 5X M9 salts 
     Na2HPO4 : 33.9g  
     KH2PO4 : 15g  
… NaCl : 2.5g  
… NH4Cl : 5.0g 
 
2mL of 1M MgSO4  
 
20mL of 20% Glucose  
 
0.1mL of 1M CaCl2  
 
Weigh out 500mg of 19 amino acids and add into 1L M9 media 
 
Microwave 1-2mins to aid dissolution  
 
Cool and pH to 7  
 
Add 100mg of 15N amino acid  
 
Sterile filter  
Pour into sterile 6L flask 
 
Growth conditions  
Start growth at 37°C (1mL of MDAG starter into 1L of M9 media)  
 
 Shake at 225rpm  
 
 Induce with IPTG when O.D. is between 0.6 and 0.7 (usually takes 4-5hr) 
 
 6hr growth after inducing  
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Chapter 3: Structural characterization of the caveolin-1 C-terminal domain 
Abstract 
 The structural characterization of caveolin-1 has been focused on short non-
functional peptides. While these studied have given invaluable insight into caveolin-1, 
there is a need to study not only a longer construct which contains all the caveolin-1 
domains but also a construct that has been shown to be functional. Caveolin-1 residues 
62-178 contain the functional portion of the N-terminal domain and the intact 
scaffolding, intramembrane and C-terminal domains. Importantly this construct has been 
shown to be functional in vivo. Additionally, the intact C-terminal domain has not been 
previously characterized, but has been shown to be vital for the biological function of 
caveolin-1. Complete backbone assignments of caveolin-1(62-178) were made, and it 
was determined that residues 62-80 were dynamic, residues 89-107, 111-128, and 132-
175 were helical, and residues 81-88, 108-110, and 129-131 represent unstructured 
breaks between the helices. When this construct was compared to one lacking the C-
terminal domain (residues 62-136), it was observed that its presence produced modest but 
significant chemical shift perturbations in the regions 80-103 and 129-136.   
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Introduction 
Typically, caveolin-1 is divided into four domains: the N-terminal domain 
(residues 1-81), the scaffolding domain (residues 82-101), the intramembrane domain 
(102-134), and the C-terminal domain (residues 135-178) (figure 1-3).  The N-terminal 
domain has been identified as a key binding domain within caveolin-1 interacting with 
other molecules and also cholesterol (59, 102). The intramembrane domain is postulated 
to be the critical structural domain of caveolin-1. It has been shown that the 
intramembrane domain contains a helix-break-helix motif and that the break is the 
location of the intramembrane turn which gives caveolae its shape (64). Arguably the 
most characterized domain within caveolin-1 is the scaffolding domain.  The scaffolding 
domain peptide has been identified as the major binding and oligomerization domain 
within caveolin-1 (66). The scaffolding domain is postulated to interact with several 
signaling molecules such as SRC kinase and endothelial nitric synthase (103, 104). 
Additionally, the scaffolding domain contains a cholesterol recognition amino acid 
consensus (CRAC) motif, however, the role of this motif in cholesterol recognition is 
unclear (45).  
Surprisingly, very little is known about the C-terminal domain. The initial 
characterization of the C-terminal domain was based on primary sequence analysis which 
predicted that it formed an amphipathic helix which rests on the surface of the membrane 
(9, 53).  The location of the C-terminal domain at the membrane surface is supported by 
the presence of three cysteine residues in the C-terminal domain that have been shown to 
be palmitoylated in vivo, and that the C-terminal domain is important for membrane 
attachment (31, 65).  
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However, there have been no experimental studies to validate these conclusions 
despite the fact that biological studies have demonstrated that the C-terminal domain is 
vital for the overall function of caveolin-1.  The C-terminal domain plays important roles 
in the movement of the protein from the Golgi apparatus to the plasma membrane and in 
membrane attachment (58, 65). In vivo, caveolin-1 is isolated as a high molecular weight 
oligomeric complex.  The initial oligomerization of caveolin-1 has been attributed to the 
scaffolding domain (residues 82-101), but the formation of networks of oligomers has 
been shown to be governed by the C-terminal domain (66).  This implies that the C-
terminal domain is required for the formation of the hallmark striated coat that is formed 
at the membrane surface to help stabilize caveolae (33).  Additionally, many caveolin-1 
binding partners such as endothelial nitric oxide synthase, connexin, and Retrovirus 
NSP4, interact directly with the C-terminal domain making it an important binding region 
within caveolin-1 (37, 67, 68).  Clearly, the C-terminal domain plays a plethora of 
important biological roles. To begin to understand the structural context of the C-terminal 
domain in caveolin-1, the secondary structure of a construct of caveolin-1 containing 
residues 62-178 which includes the C-terminal domain was determined using NMR 
spectroscopy.  This construct is functional as it has been shown to have a behavior in vivo 
that is indistinguishable from that of the wild-type protein (58).   
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Materials and Methods 
Design of Caveolin-1 constructs 
Caveolin-1 residues 62-178 (Caveolin-1(62-178)) was expressed as a TrpLE 
fusion in E. coli (see appendix 3-1).  Methionine 111, which is not strictly conserved with 
respect to the other caveolin isoforms, was mutated to leucine to facilitate cyanogen 
bromide cleavage.  Caveolin-1 has three sites of cysteine palmitoylation (133, 143, 156). 
However in vivo studies have clearly shown that removal of palmitoylation by mutation 
of cysteine residues 133, 143, and 156 to serine, does not affect the correct trafficking of 
the protein to caveolae (31). 
  
NMR sample preparation 
Uniformly 15N-labeled caveolin-1(62-178) was prepared as described previously 
by Diefenderfer et al and Studier et al (95, 105). 2H, 15N, and 13C labeled samples were 
prepared as described in Marley et al (96) (described in detail in Chapter 2).  To aid in 
the assignment of the Caveolin-1(62-178) spectra, specific amino acid labeling was 
employed (I, V, F, S, A, L, Y) using previously described methods (64, 106). Caveolin-
1(62-178) NMR samples were prepared by dissolving 6.5 mg, of lyophilized protein into 
600 μL of buffer containing 100 mM lyso-myristoylphosphatidylglycerol, 20 mM 
phosphate pH 7.0, 100 mM sodium chloride and 10% (v/v) D2O to yield a 1 mM sample. 
Samples were then filtered through a 0.2 mM regenerated cellulose spin filter. 
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NMR experiments 
         TROSY-based pulse programs were utilized for NMR experiments (107, 108). 
The 1H-15N HSQC, HNCA, HNCACB, HNCACO, and HNCO experiments were 
acquired on a 600 MHz Bruker Avance II NMR spectrometer equipped with a cryoprobe. 
Additional HNCA and 1H-15N HSQC experiments performed on caveolin-1(62-178) were 
acquired on an 850 MHz Bruker Avance III NMR spectrometer equipped with a room 
temperature probe. The spectra were processed using NMRpipe and Sparky (109, 110). 
The assigned chemical shifts were then processed using TALOS+ (111). 
  
Chemical shift perturbation 
 The chemical shift perturbation plot was prepared using the method of Ziarek et al, using 
the average amide chemical shift differences from caveolin-1(62-178) and an equivalent 
data set from a construct containing residues 62-136(112).   
Equation 3.1 
 
  
Chemical shift index plot 
The chemical shift index plot was generated by subtracting the reference Cα chemical 
shift from the observed Cα chemical shift for each residue (101). If the ΔCα is + 0.7 from 
the reference Cα, the residue cannot be assigned a consensus secondary structure and is 
labeled as ambiguous or coil. A stretch of positive ΔCα values is indicative of α-helical 
secondary structure. 
 
     22 1.0 NHN  
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Circular Dichroism spectroscopy 
Circular dichroism experiments were performed using a JASCO circular 
dichroism spectrophotometer (Easton, MD). The experiments were carried out at 37°C in 
a 0.1 mm cuvette. The blank and protein spectra were collected from 260 to 190 nm using 
a bandwidth of 1 nm, a step size of 0.5 nm and 16 accumulations. 
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Results and Discussion  
Circular dichroism spectroscopy of caveolin-1(62-178) 
To determine the overall secondary structure of caveolin-1(62-178) circular 
dichroism was performed. From the spectrum it is clear that caveolin-1(62-178) has 
significant helical character based on the minima at 208 nm and 222 nm and the 
maximum at 190 nm (Figure 3-1). This agrees well with previous data that the 
scaffolding and intramembrane domains are mostly helical with only small non-helical 
regions. This also gives insight that the C-terminal domain is also helical. This result 
agrees with previous primary sequence analysis that predicted the C-terminal domain is 
an amphipathic helix (53). 
 
 
Figure 3-1. CD spectrum of caveolin-1(62-178) (113).  
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Secondary structure assignment of caveolin-1(62-178) 
To begin to form a better understanding of the secondary structure of caveolin-
1(62-178), chemical shifts were obtained for the HN, N, Cα, Cβ and CO using NMR 
spectroscopy.   Utilizing the chemical shifts from all of the experiments it is possible to 
make complete backbone assignments of caveolin-1 (62-178) in lyso-
myristoylphosphatidylglycerol (LMPG) micelles (Figure 3-2).  From the spectrum, it can 
be seen that there is significant overlap between the peaks.  This can make assigning 
chemical shifts challenging and therefore specific amino acid labeling can be employed 
to help identify which peaks in the HSQC correspond to particular residues by overlaying 
with the wild type spectrum.  
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Figure 3-2. Assigned 1H-15N TROSY-HSQC spectrum of caveolin-1(62-178). The 
spectrum was acquired with 256 complex points in t1 (15N) and 2048 complex points in 
t2 (1H) (113). 
 
Chemical shift index plot 
 With the chemical shifts obtained from the HNCA it is possible to create a 
chemical shift indexing plot (CSI).  This plot is generated by subtracting the reference Cα 
chemical shift from the experimentally determined Cα.  A long stretch of positive ΔCα 
indicates helical structure, while a long stretch of negative ΔCα indicates β-strand. The 
CSI plot of caveolin-1(62-178) shows three long stretches of positive ΔCα values (Figure 
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3-3). Importantly, the C-terminal domain shows significant helical character. Differences 
in Cα chemical shifts that fall below standard error cannot be assigned a secondary 
structure and are labeled as ambiguous (seen in red in Figure 3-3).  Because of this 
ambiguity it is necessary to refine the structural prediction to include more parameters 
than just the Cα chemical shift. 
 
Figure 3-3. Chemical shift index plot of caveolin-1(62-178).  A) Plot of the difference 
between the observed Cα and the reference Cα. Red indicates differences that are 
predicted as a coil. B) Normalized plot of the chemical shift difference. If the ΔCα is 
greater than 0.7 ppm  it is denoted as +1, if it is less than 0.7 ppm it is denoted as -1. If 
the ΔCα  falls within + 0.7 it is denoted as 0 (113). 
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Talos+ prediction for caveolin-1(62-178) 
To further refine the structural prediction the chemical shifts for the H, N, Cα, Cβ 
and CO can be entered into a program called Talos+(111).  This program utilizes a data 
base of possible Ψ and Φ angles compiled from the Protein Data Bank (PDB) to predict 
secondary structure.  Based on the Talos+ data for cavoelin-1 (62-178), residues 62-80 
are dynamic, and residues 81-88 are unstructured.  The first major helix (Helix-1) begins 
at residue 89 and ends at residue 107.  Helix-1 is immediately followed by a three residue 
break (residues 108-110), and helical character is restored for the second helix (Helix-2) 
from residues 111-128.  Following the second helix there is another break (residues 129-
131), and the third helix (Helix-3) begins at residue 132 and continues throughout the 
entire C-terminus until residue 175, just three residues from the end of the protein (Table 
3-1).   
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Table 3-1. Talos+ data showing PHI and PSI angles and structural prediction for 
caveolin-1(62-178).  
Residue PHI PSI Prediction Residue PHI PSI Prediction Residue PHI PSI Prediction
D 9999 9999 None R -61.62 -40.988 α-helical E -60.362 -39.526 α-helical
V -117.321 140.184 Dynamic L -62.945 -45.523 α-helical I -68.431 -40.674 α-helical
V -98.852 140.681 Dynamic L -61.803 -43.21 α-helical Q -61.136 -39.474 α-helical
K -86.934 135.048 Dynamic S -62.99 -39.766 α-helical S -62.432 -43.565 α-helical
I -115.187 133.807 Dynamic A -63.742 -40.386 α-helical I -65.465 -41.017 α-helical
D -87.828 118.907 Dynamic L -67.175 -34.864 α-helical S -64.929 -37.017 α-helical
F -117.577 140.82 Dynamic F -86.489 -1.962 α-helical R -67.177 -40.212 α-helical
E -98.677 137.93 Dynamic G 90.214 9.977 unstructure V -61.347 -42.183 α-helical
D -93.109 -15.174 Dynamic I -89.661 125.897 unstructure Y -63.416 -41.266 α-helical
V -117.85 127.953 Dynamic P -58.943 142.1 unstructure S -60.548 -45.107 α-helical
I -95.148 -16.137 Dynamic L -54.638 -40.897 α-helical I -67.659 -37.573 α-helical
A -94.14 161.392 Dynamic A -60.066 -41.349 α-helical Y -76.52 -26.175 α-helical
E -83.383 136.48 Dynamic L -65.017 -41.983 α-helical V -64.181 -42.309 α-helical
P -69.411 148.881 Dynamic I -63.991 -44.258 α-helical H -61.073 -39.411 α-helical
E -83.036 131.988 Dynamic W -63.474 -42.16 α-helical T -69.467 -40.842 α-helical
G 77.638 10.305 Dynamic G -63.02 -42.879 α-helical V -64.894 -42.646 α-helical
T -60.375 -40.752 α-helical I -67.192 -41.003 α-helical S -68.881 -35.395 α-helical
H -62.201 -43.477 α-helical Y -60.738 -47.006 α-helical D -64.083 -29.33 α-helical
S -69.838 -30.784 α-helical F -61.871 -38.994 α-helical P -61.307 -31.309 α-helical
F -67.965 -35.879 α-helical A -68.165 -37.271 α-helical L -65.061 -33.635 α-helical
D -79.402 -10.415 Dynamic I -68.3 -40.731 α-helical F -66.847 -38.394 α-helical
G 83.88 16.12 Dynamic L -60.708 -40.015 α-helical E -63.494 -39.21 α-helical
I -66.724 -30.6 Dynamic S -66.899 -37.863 α-helical A -62.584 -42.532 α-helical
W -82.081 -12.267 Dynamic F -65.25 -37.881 α-helical V -66.754 -45.248 α-helical
K -74.811 -23.705 Dynamic L -68.56 -29.35 α-helical G -62.369 -41.34 α-helical
A -68.808 -34.485 Dynamic H -66.141 -31.693 α-helical K -61.988 -44.874 α-helical
S -69.594 -37.612 Dynamic I -68.037 -31.438 α-helical I -63.213 -40.285 α-helical
F -63.791 -44.832 α-helical W -78.083 -21.061 unstructure F -65.829 -39.891 α-helical
T -65.071 -42.496 α-helical A -73.668 -24.403 unstructure S -69.557 -39.306 α-helical
T -64.177 -37.429 α-helical V -106.043 -4.654 unstructure N -63.707 -44.413 α-helical
F -64.524 -42.047 α-helical V -86.852 122.377 unstructure V -65.121 -45.18 α-helical
T -63.011 -39.14 α-helical P -58.481 -28.698 α-helical R -63.348 -35.143 α-helical
V -63.326 -43.505 α-helical S -63.951 -28.902 α-helical I -63.805 -41.515 α-helical
T -69.525 -27.472 α-helical I -74.2 -26.635 α-helical N -60.76 -39.417 α-helical
K -95.073 -0.768 α-helical K -69.701 -28.726 α-helical L -63.957 -34.102 α-helical
Y -56.442 -41.535 α-helical S -62.877 -41.358 α-helical Q -76.931 -23.509 α-helical
W -65.703 -19.831 α-helical F -62.39 -45.533 α-helical K -93.168 0.649 unstructure
F -88.905 -37.898 α-helical L -65.326 -39.301 α-helical E -78.731 131.915 unstructure
Y -64.418 -42.732 α-helical I -64.97 -45.485 α-helical I 9999 9999 None
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Caveolin-1 residues (62-178) adopts a helix-break-helix-break-helix motif, with 
the previously uncharacterized C-terminal domain forming a long amphipathic helix 
(Figure 3-4) This data agrees well with the CSI plot but has the added resolution of 
relying on five chemical shift parameters rather than one.  One important note is that both 
Helix-2 and Helix-3 start with proline residues (P110 and P132).  It has been shown 
previously that having a proline at the start of a helix is a common feature in many helical 
proteins, and that the presence of a proline residue at the start of a helix may be 
energetically favorable (114). 
 
Figure 3-4. Cartoon representation of TALOS+ data for caveolin-1(62-178).  Zigzag line 
denotes dynamic structure. Purple, N-terminal domain; green, scaffolding domain; red, 
intramembrane domain; blue, C-terminal domain (113). 
 
Chemical shift perturbation plot 
Finally, there has been some indication that the scaffolding domain and the C-
terminal domain play similar roles in caveolin-1 function.  The C-terminal domain plays 
an important role in membrane attachment, and in the formation of the homo-typic 
network of oligomers that help to shape caveolae (65, 66).  Caveolin-1 is thought to 
oligomerize in vivo and to form high order complexes. The initial oligomerization has 
been isolated to the scaffolding domain (82-101) but the formation of networks of 
oligomers has been shown to be isolated to the C-terminal domain (66).  This implies that 
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the C-terminal domain is required for the formation of the striated coat that is formed at 
the membrane surface to help stabilize caveolae (33).  The C-terminal region is also 
required for the movement of the protein from the Golgi apparatus to the plasma 
membrane (58). Many caveolin-1 binding partners such as endothelial nitric oxide 
synthase, connexin, and Retrovirus NSP4, also interact directly with the C-terminal 
domain making it an important binding region within caveolin-1 (37, 67, 68).  Because of 
the overlap in function between these two domains, it has been proposed that these 
domains may be spatially close.  To examine this hypothesis, a chemical shift 
perturbation plot was made (Figure 3-5).  This plot is generated by examining the 
difference between the amide chemical shifts for two separate constructs. In this case, 
caveolin-1(62-178) was compared to caveolin-1(62-136), which is the same construct 
except it is lacking the C-terminal domain.  The largest chemical shift perturbation can be 
seen in the scaffolding domain indicating that the C-terminal domain is in close 
proximity to the scaffolding domain.  There is also a significant perturbation at the C-
terminal residues of caveolin-1(62-136), but this is expected because of the addition of 
the C-terminal domain in caveolin-1(62-178).  
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Figure 3-5. Chemical shift perturbation plot comparing caveolin-1(62-136) and caveolin-
1(62-178). Dashed line indicates the threshold for significance. Residues that experience 
significant perturbation are underlined in red (113).  
 
Analysis of the two critical break regions in caveolin-1(62-178) 
Interestingly, the caveolin-1 structure appears to be governed by two break 
regions (break 1 residues 108-110 and break 2 residues 129-131).  Break 1 has been 
previously reported to have three critical residues (Glycine, isoleucine and proline). 
Previous reports have identified that it is critical to have a small amino acid (glycine or 
alanine) followed by a β-branched amino acid (valine or isoleucine) and ending with a 
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proline (64). When examining break 2 there is a similar trend in the sequence with 
(alanine, valine, valine, proline) . Here again there is a small amino acid side chain 
followed by a β-branched side chain,   and ending with a proline; however there is an 
additional β-branched amino acid within the second break implying that the second break 
needs to be longer then the first.  Another difference is that proline 132 (end of break 
two) is predicted to be at the start of Helix-3 as opposed to P110 (end of break 1) which 
is not predicted to be helical. Previous studies have shown that proline residues are 
favorable to initiate helices, so the presence of proline residues at the start of Helix-2 and 
Helix-3 is significant (114). The presence of the same characteristic amino acid sequence 
draws similarities between break 1 and break 2. This also has functional implications. 
Break 1 is thought to occur in the membrane and help to give caveolin-1 its horseshoe 
like shape that helps to curve the membrane and form caveolae. The presence of proline 
110 has been shown to be critical for the horseshoe topology of caveolin-1 that places 
both the N- and C-termini on the cytoplasmic side of the membrane (115). Here break 2 
allows for the transition of the protein from an intramembrane helix to an interfacial helix 
that interacts intimately with the membrane at the head group region. Proline 132 (located 
at the start of Helix-3) has also been implicated as an important residue in breast cancer 
and its mutation has been shown to cause structural changes that disrupt trafficking (44, 
116, 117) (Figure 3-6). This highlights that the presence of the two proline residues at the 
end of each break is critical for the proper structure and function of caveolin-1.  
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Figure 3-6. Cartoon representation of the hypothesized topology of caveolin-1.  The 
three helices are highlighted along with the two break regions.  
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Conclusions 
The determination of the secondary structure of caveolin-1(62-178) represents a 
critical step forward in the understanding of caveolin-1 structure.  Using a functional 
construct, this is the first report of specific secondary structural data on the C-terminal 
domain of caveolin-1 and suggests that it is an amphipathic helix. Additionally, this is the 
first structural data on an elongated construct of caveolin-1 (the longest that has been 
structurally characterized) to produce a clearer picture of the secondary structure of 
caveolin-1 as a whole.  The identification of two critical break regions allows for a deeper 
understanding of how caveolin-1 is structured in the membrane.  Break-1 is the location 
of the intramembrane turn which allows for the C-terminus to return to the cytoplasmic 
side of the membrane.  Break-2 allows for the transition of Helix-2, which is located in 
the membrane to Helix-3 which is resting on the membrane surface.  The determination 
of the structure of the C-terminal domain also has important implications in disease states 
because the C-terminal domain has been shown to interact with several of the caveolin-1 
binding partners.  The disruption of the C-terminal helix has been implicated in 
pulmonary arterial hypertension, by interfering with the binding of eNOS with caveolin-1 
(42).  Therefore, the structural characterization of the C-terminal domain is a vital step in 
understanding the biological function of caveolin-1. 
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Appendix 3.1-Protein sequence for NMR studies  
Caveolin-1(62-178) 
_M11L_C133S_C143S_
C156S 
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYWFYRL
LSALFGIPLALIWGIYFAILSFLHIWAVVPSIKSFLIEIQS
ISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEI 
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Chapter 4. Alanine and phenylalanine scanning of caveolin-1(82-136).  
Abstract 
The previous chapters described the determination that the caveolin-1 
intramembrane domain contains a helix-break-helix motif.  Because of this unique motif 
it can be postulated that specific residues may be important for the motif stability.  
Additionally, it has not been established if these two helices interact with one another to 
garner additional stability.  Sequence alignment of the three caveolin-1 isoforms revealed 
strictly conserved residues (residues that are the same in all three isoforms) in the 
scaffolding and intramembrane domains.  To probe the importance of individual residues 
to the structure of caveolin-1, alanine and phenylalanine scanning was performed on all 
strictly conserved residues in the scaffolding and intramembrane domains of caveolin-1 
(82-136).  Nuclear magnetic resonance  studies revealed that mutations to residues Y100, 
P110, A112, G116, S123, H126, and P132 are “not tolerated”, while mutations to S88, 
F92, K96, Y97, L103, F119, A120, I127, and W128 are “tolerated”. Based on these 
findings, a preliminary model of helix interaction can be presented.  Additionally, this is 
the first identification of a conserved face within Helix-2 that may be important for the 
structure or function of caveolin-1.  
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Introduction 
 The relationship between protein structure and function has been emerging for 
several decades. The idea that the protein sequence can predict the overall fold of the 
protein is an attractive hypothesis when trying to assign de novo protein structure.  In fact 
in many cases the mutation of one amino acid can have significant effects on the protein 
structure and lead to disease states. For example, in the caveolin family of proteins, 
Proline 132 has been identified to be critical for the proper structure of caveolin-1. 
Mutation to leucine causes a change in cellular trafficking and has been implicated in 
breast cancer (44, 50).  Utilizing NMR spectroscopy it has been shown that the mutation 
of proline 132 to leucine causes an extension of Helix-2 and removes the second break 
which separates Helix-2 and Helix-3.  Additionally, caveolin-1 P132L has been shown to 
behave as a dimer in vitro in contrast to the wild-type protein that has been shown to be 
monomeric (44).  Importantly, Proline 132 is highly conserved between the three 
caveolin-1 isoforms.  In caveolin-3, the analogous proline residue (P104) has been linked 
to misregulation of caveolin-3 and muscular dystrophy (118).  This shows that single 
point mutations can have a dramatic effect on caveolin-1 structure and function.  
Because of the unique fold of caveolin-1 it can be hypothesized that the two 
helices in the membrane may interact or that residues within the helices are critical for 
the fold.  As discussed in Chapter 1, the three caveolin isoforms have a significant 
amount of sequence similarity (see Figure 1-3).  In particular  the scaffolding and 
intramembrane domains are highly conserved between the three isoforms.  The high 
degree of conservation is an important observation because the scaffolding and 
intramembrane domains are part of the helix-break-helix motif that is thought to help 
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shape caveolae in the cellular membrane.  While the break region (G108, I109 and P110) 
have been probed for their structural importance the role of the remaining residues with 
the helices has not been established (64).  How these residues interact within a structural 
context can have a drastic effect on how the tertiary structure of this protein is viewed.  
To determine amino acids that are critical for protein stability and structure, a 
common technique used is alanine scanning mutagenesis (119). Alanine is used because 
it is not bulky; it is chemically inert and can adopt the secondary structure preferences of 
most other amino acids. In addition, phenylalanine scanning mutagenesis probes the 
importance of steric bulk within a helix because phenylalanine has a large side chain. In 
this study, strictly conserved residues within the scaffolding and intra-membrane domains 
of caveolin-1 were mutated individually to both alanine and phenylalanine, and subjected 
to NMR experiments to determine the effect that each mutation has on the spectrum (1H-
15N HSQC). These studies revealed that residues Y100, P110, A112, G116, S123, H126 
and P132 may be critical for the structure of the protein, while alanine and phenylalanine 
mutations to residues S88, F92, K96, Y97, L103, F119, A120, I127 and W128 are 
unlikely to be critical for the structure.  
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Materials and Methods 
Protein preparation 
A caveolin construct that contains the scaffolding domain and the intra-membrane 
domain (residues 82-136) was chosen for this study (see Appendix 4-4).  Uniformly 15N-
labeled caveolin-1 (82-136) wild-type and mutant constructs were prepared as described 
previously by Diefenderfer et al. (95). Methionine 111, which is not strictly conserved, 
was mutated to leucine to facilitate cyanogen bromide cleavage. The cysteine at position 
133 was also mutated to serine to prevent non-biologically relevant disulfide bonding. 
Previous studies have shown that the mutation of cysteine 133 to serine does not affect 
the trafficking of caveolin-1 to the membrane (31). For this chapter, the notation “wild-
type caveolin-1” refers to caveolin-1(82-136) M111L C133S. Primers were designed 
utilizing the wed-based PrimerX (see Appendix 4-5). Mutations were introduced using 
the Quikchange site-directed mutagenesis kit (Aligent Technologies, Santa Clara, CA) 
(see Appendix 4-1). All mutations were confirmed by DNA sequencing analysis. 
Constructs were transformed into Bl-21(DE3) cells for protein expression (see Appendix 
4-2 and 4-3).  
  
NMR sample preparation 
NMR samples were prepared by dissolving lyophilized protein to 1 mM in 600 
μL of a buffer containing the following components: 100 mM LMPG (lysomyristoyl-
phosphatidylglycerol), 20 mM phosphate pH 7.0, 100 mM NaCl, and 10% D2O. The 
sample was vigorously mixed and heated until a clear homogenous solution was 
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obtained. Finally, the sample was filtered through a 0.2 μm regenerated cellulose spin 
filter (Grace Davison Discovery Science, Deerfield, IL).   
 
NMR experiments 
NMR experiments were performed at 37°C using a 600 MHz Bruker Avance II 
spectrometer equipped with a cryoprobe.  TROSY-based 1H-15N HSQC experiments were 
utilized for all mutations (107, 108).  All NMR spectra were processed using NMRpipe 
and Sparky (109, 110).  
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Results and Discussion 
Identification of strictly conserved residues in the three caveolin isoforms 
          Sequence alignment of the three caveolin isoforms shows that there are nineteen 
strictly conserved residues: D82, W85, S88, F92, K96, Y97, Y100, L103, P110, A112, 
G116, F119, A120, S123, H126, I127, W128, P132 and K135 (Figure 4-1). Alanine and 
phenylalanine scanning mutagenesis was carried out and 1H,15N HSQC spectra were 
generated for each residue, with the exception of D82, W85 and K135 because of their 
proximity to the ends of the construct, to elucidate their importance for protein structure. 
If the residue is critical, the 1H, 15N HSQC spectrum will show a global disruption when 
compared to the wild-type spectrum and the mutation can be classified as “not tolerated”. 
The evaluation of a global structural change was defined as a loss in peak dispersion 
and/or a decrease in the number of peaks observed and/or chemical shift changes of a 
majority of the residues. If a residue is not critical, then the spectrum will overlay very 
well with the wild-type spectrum (less than 10% chemical shift changes) and the 
mutation can be classified as “tolerated”.  
 
 
Figure 4-1. Sequence alignment of the three caveolin isoforms. The strictly conserved 
residues are highlighted in red. The three terminal conserved residues are highlighted in 
grey.  
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NMR analysis of strictly conserved residues in the scaffolding and intramembrane 
domains of caveolin-1 
Table 4-1 presents the findings of our NMR analysis. Of the sixteen strictly 
conserved residues, nine (S88, F92, K96, Y97, L103, F119, A120, I127, W128) were 
found to show no significant changes when compared to the wild-type spectrum and were 
thus labeled as “tolerated” (see Figures 4-2, 4-3, 4-4 and 4-5). The seven remaining 
conserved residues (Y100, P110, A112, G116, S123, H126 and P132) show significant 
changes when compared to the wild-type TROSY-HSQC spectrum and were thus labeled 
as “not tolerated” (see Figures 4-2, 4-3, 4-4 and 4-5). It is important to note that these 
spectral changes could represent changes other than structural ones such as aggregation 
and/or specific detergent effects. However, because it is not possible to perform NMR 
studies in other detergents, these studies cannot elucidate these detergent effects.  
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Table 4-1.  Results of alanine and phenylalanine scanning of the strictly conserved 
residues within caveolin-1(82-136) 
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Figure 4-2.TROSY-HSQC spectra of Helix-1 alanine mutants.  Wild-type is included in 
the first panel as a comparison. F) Y100A which shows significant disruption compared 
to the wild-type.  
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Figure 4-3. TROSY-HSQC spectra of Helix-1 phenylalanine mutants. Wild type is 
included in the first panel for comparison.  E) Y100F which shows significant disruption 
compared to the wild-type.  
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Figure 4-4. TROSY-HSCQ spectra of Helix-2 alanine mutants. Wild-type is included in 
the top panel for reference.  
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Figure 4-5. TROSY-HSQC spectra of Helix-2 phenylalanine mutants.  Wild-type is 
included in the top panel for comparison.  
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In contrast to Helix-2, nearly all conserved residues within Helix-1 are 
“tolerated”.  The only residue that is critical is Y100 (figure 4-2F and figure 4-3E). When 
Y100 is mutated to alanine there is a disruption that could be attributed to the loss in 
steric bulk. However, phenylalanine is also “not tolerated”. This leads to the hypothesis 
that the hydroxyl group on the tyrosine side chain is needed to stabilize the caveolin 
structure through a hydrogen bonding interaction. 
Most of the remaining conserved residues within Helix-1, (F92 and Y97) 
including S88 which directly precedes the start of the helix, reside within the more 
soluble scaffolding domain (Figure 4-2B, D, G and Figure 4-3B, D, F).  This domain is 
implicated in binding signaling proteins (e. g. endothelial nitric oxide synthase), and the 
current study supports the postulation that this region may be more important for binding 
than structure. For example, previous studies have shown that when F92 is mutated to 
alanine, caveolin-1 no longer binds to endothelial nitric oxide synthase, but the current 
study shows that this mutation was “tolerated” (120).  Therefore the scaffolding domain 
may be permissive towards mutations structurally but not functionally. The remaining 
residue, L103, is the only conserved residue within Helix-1 to reside in the intra-
membrane domain and mutations at this position are “tolerated”. This suggests that 
Helix-1 is permissive to mutations structurally; however overall this may have larger 
implications functionally. 
The only other residue to show disruption when mutated to phenylalanine is K96 
(Figure 4-3C).  However, when K96 is mutated to alanine there are no significant 
changes to the overall structure.  This indicates that there could be steric effects at 
position 96 that cannot tolerate the bulk of phenylalanine.  However, because alanine is 
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“tolerated” at this position, K96 is not considered critical for the overall structure of 
caveolin-1(82-136) (Figure 4-2C).  
Studies have shown that P110 is a critical residue that is found in the break region 
and is proposed to participate in the formation of the putative intramembrane turn that is 
the cause of the N- and C- termini lying on the same side of the plasma membrane. 
Recent results from the Glover lab also support that proline is needed at position 110 to 
stabilize the caveolin-1 structure based on mutations to alanine, and glycine (64).  
Additionally, circular dichroism and fluorescence spectroscopy studies have identified 
that the mutation of proline 110 has dramatic effects on the structure and topology of 
caveolin-1(121).  The results of the current study are in agreement with the previous 
studies indicating that mutations at proline 110 are “not tolerated” (Figure4-4B and 
Figure 4-5B). 
 
Analysis of the conserved face in Helix-2 
The remaining conserved residues (A112, G116, F119, A120, S123, and I127), 
with the exception of W128 and P132, are contained within Helix-2.  To analyze these 
residues, the angular position was tabulated with respect to A112 (the first conserved 
residue in Helix-2). Figure 4-6A shows this data. Interestingly, mutations to the 
conserved residues that are within 40 degrees of A112 are all “not tolerated” with the 
exception of F119 (Figure 4-6B). Mutations to A120 and I127 which lie outside of that 
range are “tolerated” (Figure 4-4G and Figure 4-5E and H). This is indicative of a 
conserved face within Helix-2 that may be important for interactions with Helix-1 or 
other structural contacts. 
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Figure 4-6. A) Conserved residue positioning in Helix-2. (A112 is referenced as 0). B) 
Graphical representation of conserved residue positioning in Helix-2. Residues within the 
face are highlighted in yellow, those outside in green. 
 
A112 is the first conserved residue in Helix-2 (Figure 4-6B). When a 
phenylalanine residue is placed at position 112 it introduces steric bulk that is not 
tolerated (Figure 4-5C).  This suggests that this position is geometrically restricted and is 
S123
G116
I127
H126
F119
A120
-80 -60 -40 -20 0 +20 +40 +60 +80
A112
Residue  *
M111 -100 -100
A112 0 0
L113 100 +100
I114 200 +160
W115 300 +60
G116 400 +40
I117 500 -140
Y118 600 -120
F119 700 -20
A120 800 +80
I121 900 +180
L122 1000 -80
S123 1100 +20
F124 1200 +120
L125 1300 -140
H126 1400 -40
I127 1500 +60
W128 1600 +160
A B
*: Angle with respect to A112
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the first indication of a size limitation within the conserved face. This could be due to 
intra-helix steric clashing as the i+3 position contains a large bulky residue (W115). 
The next residue within the conserved face of Helix-2 is G116.  Interestingly, 
both mutations to alanine and phenylalanine are “not tolerated” (figure 4-4C and Figure 
4-5D).  This structural disruption is not due to glycine’s high degree of conformational 
freedom as the Ψ and Φ angles based on TALOS+ calculations show that position 116 is 
helical (113). The fact that an alanine residue, which is small and comparable to glycine 
in size, is not tolerated indicates that space requirements at position 116 are extremely 
tight; only hydrogen is tolerated.  Additionally, for the G116A mutant it is unlikely that 
intra-helix steric clashing is at play due to the small size of the alanine side chain.  This 
implicates position 116 as a key interaction point within the conserved face that stabilizes 
the caveolin-1 structure and could represent a contact point with Helix-1. 
F119 is the only residue within the conserved face that “tolerated” mutation to 
alanine (Figure 4-4D).  This indicates that the bulk of phenylalanine is tolerated but not 
required to stabilize the conserved face, because the small side chain of alanine does not 
disrupt the structure. 
S123 shows disruption when mutated to both alanine and phenylalanine (Figure 
4-4E and 4-5F).  Serine has a small side chain that will not tolerate the introduction of a 
large phenylalanine residue, which is consistent with the trend of the conserved face to 
prefer smaller side chains.  Along with the issue of steric bulk, hydrogen bonding could 
also be important at position 123 because alanine is also not tolerated.  Serine and alanine 
are comparable in size but alanine lacks the hydroxyl functionality, which implies that the 
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hydrogen bonding interaction at position 123 maybe critical to stabilize the caveolin-1 
structure. 
The last structurally critical residue in Helix-2 is H126.  Similar to S123, H126 
could also participate in hydrogen bonding that is critical for the caveolin-1 structure. 
However, unlike S123, histidine has a large bulky side chain.  The disruption to the 
structure when H126 is mutated to alanine could be due to the loss in residue size, but 
there is also disruption when H126 is mutated to phenylalanine (figure 4-4F and figure4-
5G).  This indicates that size is not the key factor in the interaction of H126, but more 
likely a hydrogen bonding interaction. 
P132L has been a highly investigated mutation in caveolin-1 protein mainly 
because of its implications in cancer (122). Previous work has shown that when proline 
132 is mutated to leucine the second helix is extended and the caveolin protein behaves 
as a dimer rather than a monomer in DPC micelles (44). The current study shows that 
phenylalanine is able to stabilize the structure but alanine is not because of the loss of 
steric bulk. The structural disruption by alanine at position 132 is not due to aggregation 
because gel filtration studies have shown that the mutated protein remains a dimer and 
does not behave as a high order oligomer (44). This means that the disruption in the 
NMR spectrum is likely due to a structural loss rather than aggregation. 
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Conclusions 
Taken together, the mutagenesis data presented so far allows for the construction 
of a speculative model of caveolin structure. Previous studies have shown that the N- and 
C-termini lie on the same side of the plasma membrane, and that there is no portion of the 
protein that is accessible from the extracellular space (123, 124). In conjunction with the 
TALOS+ data previously presented,  a model can be presented where the scaffolding and 
intra-membrane domains form two equal length helices that are separated by the putative 
turn.  Clearly, with this model, residues in Helix-1 and Helix-2 that face each other and 
are close to the putative turn will be more space restricted.  This is supported by residues 
A112 and G116, as both show intolerance to additional steric bulk. In contrast, residues 
that are further from the putative turn will have less space restriction. This is 
demonstrated by the bulk of phenylalanine at position 119 being tolerated.  Also, moving 
further away from the putative turn, it appears that hydrogen bonding could dominate the 
stability as these studies revealed the need for hydroxyl functionalities at positions 100, 
123 and 126. 
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Appendix 4-1. PCR conditions 
PCR reactions with single primer 
15.8 μL sterile water 
 
0.5 μL vector DNA (50 ng/μL) 
 
0.5 μL Forward primer (250 ng/μL) 
 
2.5 μL 10X 9N Ligase buffer 
 
2.5 μL 10X PFU buffer 
 
0.2 μL DMSO 
 
1.0 μL DNTPS (25 mM) 
 
1.0 μL PFU Turbo 
 
1.0 μL 9N ligase 
 
 
PCR cycle for single primer 
Number of cycles Temperature  Time  
1 95 30 seconds 
30 95C 
 
55C 
 
68C 
30 seconds 
 
1 minute 
 
6 minutes 
End  4C indefinite 
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Appendix 4-2. XL-1 blue transformation Protocol  
1. Thaw one 100 μL aliquot of ultra-competent XL-1 blue cells on ice for 10 
minutes 
2. Place sterile 15 mL culture tube on ice for 10 minutes to pre-chill 
3. Add 100 μL of cells to the pre-chilled culture tube 
4. Add 1 μL of PCR reaction directly into cells 
5. Leave on ice for 30 minutes 
6. Heat shock at 42C for 90 seconds 
7. Leave on ice for 2 minutes 
8. Add 900 μL of SOC 
9. Incubate at 37C with shaking (250 rpm) for 1-2 hours 
10. Plate 400 μL of culture onto LB plate with kanamycin 
11. Incubate overnight at 37C 
12. Pick single colony and grow in 5 mL LB broth with kanamycin 
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Appendix 4-3. Transformation protocol for BL-21(DE3) cells 
1. Thaw one 50 μL aliquot of BL-21(DE3) cells on ice for 10 minutes 
2. Place sterile 15 mL culture tube on ice for 10 minutes to pre-chill 
3. Add 50 μL of cells to the pre-chilled culture tube 
4. Add 1 μL of 20 ng/μL of purified DNA 
5. Leave on ice for 30 minutes 
6. Heat shock at 42C for 90 seconds 
7. Leave on ice for 2 minutes 
8. Add 950 μL of SOC 
9. Incubate at 37C with shaking (250 rpm) for 1-2 hours 
10. Plate various dilutions onto MDAG plate with kanamycin 
11. Incubate overnight at 37C 
12. Pick single colony and grow in 5 mL MDG with kanamycin 
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Appendix 4-4.  Primer sequences used 
Primers for alanine mutants  
Construct  
S88A GGT ATC TGG AAA GCG GCG TTC ACC TTC ACC 
F92A GAA AGC GTC TTT CAC CAC CGC GAC CGT TAC CAA ATA CTG 
G 
Y97A CTT CAC CGT TAC CAA AGC GTG GTT CTA CCG TCT GC 
Y100A CCA AAT ACT GGT TCG CGC GTC TGC TGT CTG CG 
L103A GTT CTA CCG TCT GGC GTC TGC GCT GTT C 
S104A GTT CTA CCG TCT GCT GGC GGC GCTTTC GGT ATC 
G116A GCG CTG ATC TGG GCG ATC TAC TTC GCG  
F119A GAT CTG GGG TAT CTA CGC GGC GAT CCT GTC TTT C 
S123A CTA CTT CGC GAT CCT GGC GTT CCT GCA CAT CTG G 
H126A GAT CCT GTC TTT CCT GGC GAT CTG GGC GGT TGT TC 
I127A CGA TCC TGT CTT TCC TGC ACG CGT GGG CGG TTG TTC CGT 
CTA TC 
W128 CTG TCT TTC CTG CAC ATC GCG GCG GTT GTT CCG TCT ATC 
 
Primers for phenylalanine mutants 
Construct  
S88F GTA TCT GGA AAG CGT TTT TCA CCA CCT TCA C 
Y97F CTT CAC CGT TAC CAA ATT CTG GTT CTA CCG TCT G 
Y100F CAA ATA CTG GTT CTT CCG TCT GCT GTC TGC 
L103F GTT CTA CCG TCT GTT CTC TGC GCT GTT C 
S104F CTA CCG TCT GCT GTT CGC GCT GTT CGC GCT GTT CGG TAT C 
A112F GTT CGG TAT CCC GCT GTT CCT GAT CTG GGG TAT C 
G116F CTG GCG CTG ATC TGG TTC ATC TAC TTC GCG ATC C 
A120F GAT CTG GGG TAT CTA CTT CTT CAT CCT GTC TTT CCT GCA C 
S123F CTT CGC GAT CCT GTT CTT CCT GCA CAT CTG G 
H126F GAT CCT GTC TTT CCT GTT CAT CTG GGC GGT TGT TC 
I127F GTC TTT CCT GCA CTT CTG GGC GGT TG 
W128F CTT TCC TGC ACA TCT TCG CGG TTG TTC CGT C 
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Appendix 4-5 Protein sequences of alanine and phenylalanine mutants  
Construct Sequence of alanine mutants 
S88A DGIWKAAFTTFTVTKYWFYRLLSALFGIPLALIWGIYFAILSFLHIWAVVP
SIKS 
F92A DGIWKASFTTATVTKYWFYRLLSALFGIPLALIWGIYFAILSFLHIWAVVP
SIKS 
Y97A DGIWKASFTTFTVTKAWFYRLLSALFGIPLALIWGIYFAILSFLHIWAVVP
SIKS 
Y100A DGIWKASFTTFTVTKYWFARLLSALFGIPLALIWGIYFAILSFLHIWAVVP
SIKS 
L103A DGIWKASFTTFTVTKYWFYRLASALFGIPLALIWGIYFAILSFLHIWAVVP
SIKS 
S104A DGIWKASFTTFTVTKYWFYRLLAALFGIPLALIWGIYFAILSFLHIWAVVP
SIKS 
P110A DGIWKASFTTFTVTKYWFYRLLSALFGIALALIWGIYFAILSFLHIWAVVP
SIKS 
G116A DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWAIYFAILSFLHIWAVVP
SIKS 
F119A DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWGIYAAILSFLHIWAVVP
SIKS 
S123A DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWGIYFAILAFLHIWAVVP
SIKS 
H126A DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWGIYFAILSFLAIWAVVP
SIKS 
I127A DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWGIYFAILSFLHAWAVVP
SIKS 
W128 DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWGIYFAILSFLHIAAVVP
SIKS 
P132A DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWGIYFAILSFLHIWAVVA
SIKS 
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Construct Sequence of phenylalanine mutants  
S88F DGIWKAFFTTFTVTKYWFYRLLSALFGIPLALIWGIYFAILSFLHIWAVVPS
IKS 
Y97F DGIWKASFTTFTVTKFWFYRLLSALFGIPLALIWGIYFAILSFLHIWAVVPS
IKS 
Y100F DGIWKASFTTFTVTKYWFFRLLSALFGIPLALIWGIYFAILSFLHIWAVVPS
IKS 
L103F DGIWKASFTTFTVTKYWFYRLFSALFGIPLALIWGIYFAILSFLHIWAVVPS
IKS 
S104F DGIWKASFTTFTVTKYWFYRLLFALFGIPLALIWGIYFAILSFLHIWAVVPS
IKS 
P110F DGIWKASFTTFTVTKYWFYRLLSALFGIFLALIWGIYFAILSFLHIWAVVPS
IKS 
A112F DGIWKASFTTFTVTKYWFYRLLSALFGIPLFLIWGIYFAILSFLHIWAVVPS
IKS 
G116F DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWFIYFAILSFLHIWAVVPS
IKS 
A120F DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWGIYFFILSFLHIWAVVPS
IKS 
S123F DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWGIYFAILFFLHIWAVVPS
IKS 
H126F DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWGIYFAILSFLFIWAVVPS
IKS 
I127F DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWGIYFAILSFLHFWAVVPS
IKS 
W128F DGIWKASFTTFTVTKYWFYRLLSALFGIPLALIWGIYFAILSFLHIFAVVPS
IKS 
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Chapter 5. Functional assay of caveolin-1  
Abstract 
 The major function of caveolin-1 is to form caveolae, highly curved invaginations 
in the cellular membrane, which can be difficult if not impossible to recapitulate in vitro. 
This is due to not only the high degree of complexity in the plasma membrane but also 
the lack of detailed mechanistic knowledge of how caveolae are formed.  This can make 
it difficult to assess how mutations affect the overall function of caveolin-1 in vitro.  In 
this chapter a novel in vitro functional assay for caveolin-1 is presented.  This assay is 
based on the inhibition of endothelial nitric oxide synthase, a known binding partner of 
caveolin-1.  The assay has been validated utilizing a known small molecule inhibitor of 
eNOS L-NAME and a caveolin-1 construct that has been shown to interfere with 
inhibition (caveolin-1 F92A).  Additionally, the assay has been optimized for use with 
detergents which are necessary for caveolin-1 solubilization.  Additionally, there has 
been some evidence that the presence of C-terminal tags affect the trafficking of 
caveolin-1.  Utilizing the eNOS assay, the presence of C-terminal tags was shown to 
interfere with the function of caveolin-1, while N-terminal tags had no effect. Overall this 
assay will allow for point mutations in caveolin-1 to be evaluated not only in a structural 
context but also in the context of caveolin-1 function. 
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Introduction 
 To complement the alanine and phenylalanine scanning data presented in the 
previous chapter, a functional assay for caveolin-1 needs to be employed.  One of the 
major challenges is that the only known function of caveolin-1 is the formation of 
caveolae.  This can be difficult if not impossible to mimic in vitro, largely because the 
mechanism of caveolae formation is not known.  The mechanism of caveolae formation 
goes to the core of membrane organization.  It is not clear if lipid organization, 
cholesterol recruitment, or caveolin-1 oligomerization trigger the formation of these 
highly specialized domains (125).  Additionally, the complexity of the plasma membrane 
makes it almost impossible to mimic the exact conditions that the caveolin-1 protein 
would experience in the cell.  Studies have shown that over expression of caveolin-1 in 
vivo, which is often required to access protein function, can actually lead to disease like 
phenotypes (117).  This complicates the use of in vivo assays to determine how mutations 
effect caveolae formation because it can be difficult to determine if the lack of formation 
of caveolae is from the mutation or simply overexpression.  The fact that caveolin-1 has 
no enzymatic activity on its own,  further complicates the in vitro analysis of caveolin-1 
function. Therefore, it is necessary to form an indirect enzymatic assay with one of the 
caveolin-1 binding partners.  
 Caveolin-1 has been proposed as a binding partner to several signaling molecules. 
It was initially thought that these signaling molecules would recognize caveolin-1 for 
binding through a specific motif known as the caveolin-1 binding motif (CBM) (40). The 
CBM consists of an aromatic rich domain (фXфXXXXф, фXXXXфXXф or 
фXфXXXXфXXф, ф is an aromatic and X can be any amino acid) (40).  However, a 
91 
 
recent computational study has shown that in many of the proposed binding partners the 
CBM is buried within the structure and therefore is not accessible for binding(41).  The 
location of binding in caveolin-1 has also been questioned because all of these binding 
partners appear to bind to the scaffolding domain. This seems unlikely because the 
scaffolding domain is also described as the major oligomerization domain. If the 
scaffolding domain is involved in the formation of oligomers it seems implausible that it 
would also be available for binding to several different signaling molecules (35).  
Additionally, because several of these signaling molecules are soluble, it calls into 
question how the scaffolding domain can interact with both hydrophilic molecules and 
hydrophobic molecules such as cholesterol.  This made it difficult to find a binding 
partner that has been well established for caveolin-1 that has enzymatic function.  
 Endothelial nitric oxide synthase is an enzymatic protein that controls the 
production of nitric oxide in endothelial cells (126).  The regulation of nitric oxide has 
been shown to be important for  protection against atherosclerosis which leads to artery 
hardening, platelet aggregation and also defects in vasodilation (127).  The dysfunction of 
eNOS has been attributed to several cardiovascular diseases (128). Caveolin-1 has been 
shown to inhibit eNOS activity (129, 130, 131).  This inhibition has been shown to be 
vital to maintaining endothelial health (42).  Caveolin-1 does not completely stop the 
production of nitric oxide but rather helps to regulate the output.  In the absence of 
caveolin-1 there is a buildup of nitric oxide within the cells that leads to severe 
endothelial health defects (132).  
 There are well established assays available to quantitate the amount of nitric oxide 
that is present in solution (133).  Most of the assays rely on the reaction of nitrite with 
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2,3-diaminonaphthalene (DAN probe).  Nitrite is generated from the decomposition of 
nitric oxide into both nitrite and nitrate. To reduce the nitrate to nitrite, nitrate reductase 
is used. While nitrate is partially reactive with the DAN probe, nitrite shows a significant 
increase in reactivity.  When the DAN probe reacts with nitrite it creates the fluorescent 
compound 2, 3-naphthotriazole, and the fluorescence signal is enhanced by the addition 
of base.  By evaluating the amount of nitrite produced when eNOS is incubated in the 
presence of caveolin-1 constructs, the functional consequences of mutations can be 
evaluated.  These results can then be compared to the structural data presented in the 
previous chapter, to build an understanding of the structure/function relationship of 
caveolin-1 
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Material and methods 
Construct design 
 Full length caveolin-1 (residues 1-178) was purchased from Genscript and cloned 
into the pGEX vector which encodes for an N-terminal GST fusion utilizing Nde1 and 
Xho1 restriction sites.  The three C-terminal cysteine mutations were mutated to serine as 
previously described which has been shown to not affect caveolin-1 function.  
GST_caveolin-1_F92A was generated utilizing Agilent Quickchange site directed 
mutagenesis.  Both constructs were expressed in BL-21(DE3) cells.  Full length caveolin-
1_Myc_H6 and caveolin-1_F92A_Myc_H6 were cloned into pET 24a and transformed 
into BL-21(DE3) cells.  Purified eNOS was purchased from Cayman Chemical (Ann 
Arbor, Michigan).  The caveolin-1 scaffolding domain peptide was purchased from 
Genscript (Piscataway, New Jersey) (see appendix 5-2 for sequences).  
 Protein expression 
 All constructs were expressed utilizing the auto-induction method described in 
Studier (105).  For GST_caveolin-1 and GST caveolin-1_F92A 1L ZYM-5052 cultures 
were inoculated with 1 mL of a 5 mL overnight MDG starter and incubated for 12 hours 
with shaking (250 rpm) at 37C (see appendix 5-1).  Full length caveolin-1_Myc_H6 and 
Caveolin-1_F92A_Myc_H6 was expressed in a similar manner except that 1L ZYM-
5052 cultures were incubated at 25C for 24 hours.  All cultures were harvested by 
centrifugation at 5,807 xg for 15 minutes at 4C. Pellets were washed with 200 mL 0.9% 
(w/v) saline and centrifuged for 30 minutes at 5000 xg for 30 minutes. The supernatant 
was removed and pellets were stored at -80C until purification.  
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Purification of GST_caveolin-1 and GST_caveolin-1_F92A 
 Cell pellets were resuspended in 40 ml of 1X TAE and treated with 1 mg/ml 
lysozyme for 15 minutes on ice with stirring.  After lysozyme treatment BME was added 
to 20 mM. Cells were lysed using sonication for a total of 20 minutes (5 minutes on and 
10 minutes off). The membranes were isolated by centrifugation at 50,000 xg for 2 hours 
and the supernatant was removed.  Membrane pellets were resuspended in 40 ml of 
1XPBS 0.5% Brij with 20 mM BME and stirred on ice for 15 minutes.  Insoluble cellular 
components were removed by centrifugation for 2 hours at 50000 xg at 4C.  The 
supernatant was filtered through a 0.2 μm filter and incubated at 4C overnight with 1 mL 
of GST resin.  After overnight incubation with stirring, the solution was loaded into an 
empty Bio-rad column and the flow-through was collected.  The column was washed 
with 10 column volumes of 0.1% brij in 1 X PBS.  Protein was eluted from the column in 
1 mL fractions with elution buffer (10 mM reduced glutathione, 50 mM tris pH 8.0 and 
0.1% brij). The most concentrated fractions were pooled and concentrated to 100-200 μM 
utilizing an amicoron ultra concentrator.  
 
Purification of caveolin-1_Myc_H6 and Caveolin-1_F92A_Myc-H6 
 Pellets were resuspended in 40 ml lysis buffer (50 mM Pi pH 8.0, 300 mM NaCl, 
2% Empigen BB).  Cells were lysed by sonication for 45 minutes and the temperature 
was maintained at <10C. Lysate was cleared for 1 hour at 50000 xg and filtered through 
0.2 μm filter.  The lysate was loaded onto Ni-NTA column at a rate of 1 ml/min.  The 
column was washed with five column volumes of wash buffer (20 mM imidazole, 50 mM 
phosphate pH 8.0, 300 mM NaCl, and 0.5% Empigen BB).  Protein was eluted with 
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elution buffer (50 mM phosphate pH 8.0, 300 mM NaCl, 250 mM imidazole and 0.5% 
Empigen BB) and 1 mL fractions were collected.  The concentrated fractions were pooled 
and concentrated to 200 μL and loaded onto a Sephacryl S300 HR column (GE 
healthcare, Pittsburg, PA) in gel filtration buffer (0.5% Empigen BB, 25 mM phosphate 
pH 8.0, 150 mM NaCl). 
 
eNOS assay 
 To bench mark the assay 1 mM L-NAME was mixed with eNOS and reacted at 
room temperature for 15 minutes.  25 μL of reaction cofactor mix (50 mM Hepes pH 7.4, 
50 μM arginine, 2 mM calcium chloride, 0.5 μM BH4, 4 μM FAD, 4 μM FMN, 100μM 
calmodulin, 1 mM NADPH, 1 unit of nitrate reductase) was added and reacted for 45 
minutes at room temperature.  The reaction was quenched by the addition of 280 μL of 
DAN probe and reacted for 10 minutes.  76 μL of 3 M NaOH was added and the samples 
were diluted to 3 ml with water.  The levels of nitrite were detected by excitation at 360 
nm and emission at 410 nm.  All other reactions were carried out in a similar fashion by 
mixing varying amounts of the protein constructs (GST_caveolin-1, GST_caveolin-
1_F92A, caveolin-1_Myc_H6, caveolin-1_F92A_Myc_H6, and caveolin-1 82-101) with 
eNOS.  In all cases, the buffer that the protein was dissolved in was used in a control 
reaction with eNOS to establish that the buffer did not have an effect on eNOS activity. 
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Results and Discussion 
 Previous studies on the interaction of caveolin-1 and eNOS used Glutathione S-
transferase (GST) tagged caveolin-1 constructs of varying lengths (37).  From this study 
it was shown that there was no effect on eNOS activity in the presence of GST alone and 
that a significant decrease in activity was only observed in the presence of full length 
caveolin-1, the scaffolding domain and the C-terminal domain.  The N-terminal domain 
and intramembrane domain were shown to have no effect on eNOS activity (37).  This is 
an important finding that indicates if mutations are made outside of the C-terminal and 
scaffolding domains any change in eNOS activity can be attributed to an overall global 
structural change in caveolin-1.  In all cases, the maximum decrease in eNOS activity 
was approximately 50%. This is congruent with in vivo studies that show caveolin-1 
attenuates the production of nitric oxide but does not abolish it.  
 
Effect of detergents on eNOS activity 
 One of the challenges of investigating the interaction of caveolin-1 with eNOS is 
the presence of detergent.  Caveolin-1 contains significant hydrophobic character which 
makes it necessary to have detergents present in order to keep caveolin-1 soluble.  
However, detergents are known to be denaturing and can affect enzyme activity.  
Therefore the detergent selected for the assay must have a relatively low CMC, which 
will allow for lower concentrations of detergent.  Brij is an attractive choice because it 
has a low CMC and is also relatively inexpensive (see Appendix 5-2).  Additionally, Brij 
is a relatively mild detergent, which should not disrupt the enzyme activity.  There is no 
effect on eNOS activity at high concentrations of either Brij 35 or Brij 58 (Figure 5-1).    
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Figure 5-1. the results of eNOS activity in the presence of various amounts of Brij. The 
top panel shows reaction with 5 mM Brij 58 and the bottom panel shows reaction in the 
presence of 0%, 0.5%, 1% and 2% Brij 35  
 
Validation of eNOS assay 
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To validate that the eNOS assay was working, initially eNOS was reacted with a 
known small molecule inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME).  L-
NAME is an arginine derivative that binds to eNOS and prevents the generation of nitric 
oxide.  It has been shown in vivo that when the caveolin-1 gene is silenced there is an 
increase in eNOS activity and therefore a build-up of nitric oxide leading to pulmonary 
defects.  Treatment with L-NAME reverses the pulmonary defects and decreases nitric 
oxide levels in cells (134). When the assay is performed in the presence of 1 mM L-
NAME there is a significant decrease in eNOS activity (Figure 5-2).  
 
  
 
Figure 5-2.  A) Structure of L-NAME. B) the results of the eNOS assay in the presence of  
1 mM L-NAME.  
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It has been shown that the caveolin-1 scaffolding domain peptide (residues 82-
101) inhibits eNOS (135, 136, 137).  In vivo delivery of the caveolin-1 scaffolding 
domain  in caveolin-1 deficient mice reduces the level nitric oxide and reverses 
endothelial dysfunction (103).  Because of this well established interaction, eNOS was 
incubated with various concentrations of the purified scaffolding domain peptide to show 
a concentration dependence on inhibition (Figure 5-3). These two results prove eNOS 
enzyme is active in the context of the assay.  
 
 
Figure 5-3. Results of eNOS assay with varying amounts of the caveonlin-1 scaffolding 
domain.  Error bars based on the average of 5 trials.  
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eNOS reaction with caveolin-1 F92A 
 Alanine scanning mutagenesis of the caveolin-1 scaffolding domain revealed that 
residue 92 was critical for caveolin-1 inhibition of eNOS.  When residue 92 (a 
phenylalanine in the WT protein) was mutated to alanine, there was no inhibition of 
eNOS activity and in some studies there was actually an increase in the overall levels of 
nitric oxide (138).  Interestingly, based on the NMR data presented in chapter 4, there 
was no structural change when F92 was mutated to alanine.  In agreement with these 
studies, it has been shown that caveolin-1 F92A still binds to eNOS but does not exhibit 
the inhibitory function of wild-type (135).  In the context of the assay presented, the 
presence of the wild-type protein showed a decrease in eNOS activity while the presence 
of caveolin-1 F92A restored the eNOS activity (Figure 5-4).  All of these studies together 
show the detection of nitric oxide levels in solution in the presence of caveolin-1 is a 
good method to probe the structural effects of mutations to caveolin-1 on its function. 
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Figure 5-4. The results of the eNOS assay in the presence of N-terminal GST tagged 
caveolin-1comparing eNOS alone and in the presence of wild-type caveolin-1and F92A.  
 
Effect of C-terminal tags on eNOS activity 
The caveolin-1 C-terminal domain is the least characterized domain of the 
caveolin-1 protein. However, it appears to play a much larger role in the overall structure 
and function of the protein than previously thought.  An in vivo study conducted on 
caveolin-1 constructs containing different C-terminal tags revealed that the presence of 
these tags cause significant deviation in behavior from the wild-type protein (139).  The 
addition of bulky fluorescent tags (GFP and m-Cherry), caused larger aggregates of 
caveolin-1 to form when compared to the wild-type.  The addition of a myc antibody tag 
showed the least amount of perturbation when compared to the wild-type (139). It is 
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important to note that in all three of the C-terminal tags, none of the over-expressed 
constructs interacted with endogenous caveolin-1 in cells (139).  This shows that the 
presence of C-terminal tags causes a change in caveolin-1 trafficking and the cells do not 
recognize C-terminal tagged caveolin-1 in the same manner as the wild-type.  
 When the eNOS assay is performed in the presence of  caveolin-1_myc_his (myc 
added as an antibody tag and the histidine tag for purification), the wild type protein 
behaves identically to the N-terminally tagged protein.  However, when caveolin-
1_myc_his_F92A is reacted with eNOS there is a loss of eNOS activity (Figure 5-5A and 
5-5B).  It has been shown that the caveolin-1 C-terminal domain can inhibit eNOS 
activity to the same extent as the scaffolding domain (37).  This agrees that the presence 
of C-terminal tags has an effect on the overall structure and function of caveolin-1.   
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Figure 5-5. A) results of eNOS assay with C-terminal tagged cavolin-1 wild-type and 
F92A. B) Comparison of the results of the eNOS assay in the presence of N-terminal and 
C-terminal tagged caveolin-1_F92A.  Error bars are based on the average of 5 trials.  
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Conclusions 
 The development of an in vitro functional assay is critical for understanding the 
effects of caveolin-1 mutations.  Overall, these studies have shown that the interaction of 
eNOS with caveolin-1 can be used to probe structural changes of caveolin-1 in vitro.  
This can give a complementary data set for the alanine and phenylalanine scanning 
mutagenesis presented in chapter 4.  Importantly, this assay can be utilized to determine 
long range structural effects caused by point mutations.  Because it has been shown that 
the intramembrane domain alone does not inhibit eNOS, mutations made to this domain 
that show inhibition indicate a global structural change.  Additionally, this assay can be 
utilized to investigate how the presence of fluorescent and antibody tags affect the 
structure and function of caveolin-1.  Based on the data presented even the presence of a 
small antibody tag (in this case a myc tag) causes dramatic changes in caveolin-1 
function.  This indicates that the integrity of the C-terminal domain is essential for 
caveolin-1 biology.  Having an in vitro assay that can rapidly detect changes in caveolin-
1 function will have broad implications in the biophysical characterization of caveolin-1 
and also add a complementary technique to further elucidate how structural changes 
affect caveolin-1 function.  
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Appendix 5-1. Recipe for auto-induction media 
ZYM-5052 
20 grams NZ Amine 
 
10 grams yeast extract 
 
1916 mL water 
 
4 mL 1 M MgSO4 
 
400 μL 1000X trace metals 
 
40 mL 50x5052 
 
40 mL 50xM 
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Appendix 5-2. Protein sequences for functional assay 
Construct Sequence 
GST_caveolin-1_Myc MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCL
YGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVE
DLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGD
QISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLAS
PEYVNLPINGNGKQMSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADE
LSEKQVYDAHTKEIDLVNRDPKHLNDDVVKIDFEDVIAEPEGTHSFDGI
WKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAILSFLHIWAVVPC
IKSFLIEIQCISRVYSIYVHTVCDPLFEAVGKIFSNVRINLQKEIEQKL
ISEEDL 
GST_caveolin-
1_F92A_Myc 
MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCL
YGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVE
DLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGD
QISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLAS
PEYVNLPINGNGKQMSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADE
LSEKQVYDAHTKEIDLVNRDPKHLNDDVVKIDFEDVIAEPEGTHSFDGI
WKASFTTATVTKYWFYRLLSALFGIPMALIWGIYFAILSFLHIWAVVP
CIKSFLIEIQCISRVYSIYVHTVCDPLFEAVGKIFSNVRINLQKEIEQK
LISEEDL 
Caveolin-1_Myc_H6 MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEI
DLVNRDPKHLNDDVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYW
FYRLLSALFGIPMALIWGIYFAILSFLHIWAVVPCIKSFLIEIQCISRV
YSIYVHTVCDPLFEAVGKIFSNVRINLQKEIEQKLISEEDLHHHHHH 
Caveolin-
1_F92A_Myc_H6 
MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEI
DLVNRDPKHLNDDVVKIDFEDVIAEPEGTHSFDGIWKASFTTATVTKY
WFYRLLSALFGIPMALIWGIYFAILSFLHIWAVVPCIKSFLIEIQCISR
VYSIYVHTVCDPLFEAVGKIFSNVRINLQKEIEQKLISEEDLHHHHHH 
Caveolin-1(82-101) DGIWKASFTTFTVTKYWFYR 
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Appendix 5-3. Structure of Brij 35 and Brij 58 
Brij 58 
 
 
Brij 35 
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Chapter 6 Utilizing cysteine accessibility to determine membrane protein topology 
Abstract 
 The caveolin-1 scaffolding domain is thought to play a critical role in membrane 
attachment and the formation of the oligomeric complex.  However, the scaffolding 
domain is also reported as the major binding domain for almost all of the caveolin-1 
binding partners as well as cholesterol.  This is unusual because it indicates that the 
scaffolding domain interacts with both soluble and insoluble binding partners.  Because 
of this it is unclear what environment the scaffolding domain exists in.  To probe the 
position where the protein transitions from the aqueous environment to the plasma 
membrane, single cysteine mutations were made to residues 82-101 (the scaffolding 
domain).  Several different maleimide probes were employed to determine the 
accessibility of the scaffolding domain.  It was found that large thiol reactive groups (5 
kDa PEG) were unable to interact with the caveolin-1 protein in membranes, even when 
reacted with an exposed residue.  However, smaller thiol reactive probes (0.5 kDa and 1.2 
kDa PEG) were able to efficiently react with the cysteine residues, though several 
considerations are discussed for utilizing these small PEGs. Data acquired for single 
cysteine mutations at the four tryptophan residues agreed with previously published 
fluorescence data and showed that W85 was the most exposed and W115 (thought to be 
buried in the membrane) was the least exposed.  Overall, the determination of the 
topology of caveolin-1 is a complex problem, several considerations are presented. 
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Introduction 
  The major membrane interacting domains of caveolin-1 are the scaffolding and 
intramembrane domain.  The intramembrane domain has been shown to be extremely 
hydrophobic and therefore is thought to be membrane embedded.  However, the sequence 
of the scaffolding domain is much more variable and it is therefore not clear which parts 
of this domain are inserted in the membrane (if any).  Structural studies of the scaffolding 
and intramembrane domain have shown that these two domains for the helix-break-helix 
motif that is thought to give caveolae its shape (56, 64, 113).  However, the topology of 
the protein with respect to the membrane normal has not been determined.  In particular, 
at what residue within the scaffolding domain the protein transitions from the cytosol to 
the plasma membrane has not been established.  
The caveolin-1 scaffolding domain has been the most extensively studied domain 
within caveolin-1.  This is attributed to the fact that the scaffolding domain has been 
shown to be critical for caveolin-1 function.  It has been shown that the scaffolding 
domain interacts with several of caveolin-1 binding partners such as Src-like kinases, H-
Ras, G-proteins and eNOS (39, 104, 140).  As discussed in chapter 5, the scaffolding 
domain has been shown to inhibit eNOS activity both in vivo and in vitro (138). The 
scaffolding domain has also been shown to be important for membrane attachment.  
Removal of the scaffolding domain shows a disruption of trafficking of caveolin-1 to the 
membrane (58).  Therefore, there is a loss of caveolae at the plasma membrane when the 
scaffolding domain is removed.  The caveolin-1 scaffolding domain has been shown to 
contain a cholesterol recognition amino acid consensus (CRAC) motif (45).  Because of 
the high levels of cholesterol within caveolae, it is thought that the scaffolding domain 
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recruits cholesterol at high levels to stabilize caveolae.  Additionally, the scaffolding 
domain plays a critical role in the formation of caveolin-1 homo-oligomeric complexes 
(124).  
Because of its many roles in caveolin-1 biology, several studies have tried to 
determine the orientation of the scaffolding domain within the membrane.  These studies 
have revealed that the scaffolding domain reacts with the lipid bilayer and also is critical 
for the formation of the U-Shaped topology of caveolin-1 (141, 142).  However, the 
previous studies were conducted on peptides of various lengths that did not contain the 
intact caveolin-1 protein.  The presence of the other caveolin-1 domains may impact the 
orientation of the scaffolding domain in the membrane. As discussed in chapter 3, there is 
evidence that the C-terminal domain and the scaffolding domain may interact.  
Additionally, it has been shown that the presence of the intramembrane domain has an 
effect on the structure of the caveolin-1 scaffolding domain (56, 62).  It is therefore 
necessary to determine the topology of the scaffolding domain in the context of the full 
length protein.  
A common technique to determine the topology of a membrane protein is 
chemical accessibility assays (143).  In these assays a reactive group is inserted into the 
protein sequence at various locations and accessibility is determined using either a 
membrane permeable or membrane impermeable probe.  Therefore the exact residue 
where the protein transitions from the cytoplasm to the membrane is determined.  
Cysteine is often used to probe accessibility because it has a thiol group which has been 
shown to react in vivo with palmitic acid through a thioester bond (144).  It is therefore a 
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non-perturbing insertion that can be reacted with a variety of probes that contain thiol 
reactive groups.   
To investigate the topology of the caveolin-1 scaffolding domain in the context of 
the full length protein, 22 single cysteine mutations were made.  The E. coli membranes 
were isolated and the cysteines were probed for accessibility utilizing several thiol 
reactive probes.  By analyzing the protein in the E. coli membranes, only correctly folded 
protein that trafficked to the membrane is examined.  Initially membranes were dissolved 
in q=0.5 bicelles and reacted with biotin maleimide.  However, this method requires that 
the protein be purified because it is non-specific and all cysteine containing proteins will 
react.  Therefore membranes were reacted with maleimide PEG derivatives, which do not 
require purification because reactivity with the probe is assessed by a molecular weight 
shift.  Interestingly, the large PEG molecules showed no reactivity.  However, smaller 
maleimide PEG derivatives showed significant reaction.  By benchmarking the cysteine 
reactivity with the four tryptophan residues, whose location in the bilayer has been 
previously studied, several caveats to utilizing cysteine scanning to determine caveolin-1 
topology were discovered.  
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Materials and Methods 
Construct design and mutation  
 A full length caveolin-1 construct encompassing residues 1-178 was used as the 
template for the site directed mutagenesis and was designated as the “wild-type” 
construct (see Appendix 6-2).  The three native cysteine residues were mutated to serine 
to avoid off target reaction with the thiol reactive probe and has previously stated the 
mutation of these cysteine residues has no effect on caveolin-1 function (31). 
Additionally a Myc tag was appended to the C-terminus to allow for antibody detection 
followed by a hexa-histidine tag.  Single cysteine constructs were generated by Agilent 
Quickchange mutagenesis to generate at total of 23 constructs (cysteines at residues 82-
101, W115, W128, and tyrosine 14).  All constructs were cloned into pET 24a and 
transformed into BL-21(DE3) cells. 
 
Protein expression 
 All constructs were expressed using auto-induction media as described by Studier 
(105). 1 L cultures were inoculated with 1 mL of a 5 mL overnight culture and grown for 
24 hours at 25C.  Cells were harvested by centrifugation at 8300 xg for 15 minutes at 
4C. Pellets were washed with 200 mL of 0.9% (w/v) saline and collected by 
centrifugation at 5000 xg for 30 minutes at 4C.  
 
Membrane Isolation 
1 L cell pellets were resuspended in 40 mL 1XTAE and reacted with 1 mg/mL 
lysozyme for 15 minutes on ice with stirring.  Cells were lysed by sonication for 45 
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minutes with stirring on ice and the temperature was monitored to maintain <10C.  
Unbroken cells and cellular debris were removed by centrifugation at 30,000 xg for 30 
minutes at 4C.  The pellet was discarded and the membranes were extracted from the 
supernatant by centrifugation at 130,000 xg for 20 minutes at 4C. Membrane pellets 
were washed with 30 mL of 1XPBS containing 100 μM TCEP and pelleted by 
centrifugation at 130,000 xg for 20 minutes at 4C.  Membranes were resuspended in 1X 
PBS, 100 μM TCEP with 30% sucrose and aliquoted for storage at -80C until use in the 
assay.  
 
Phosphate Assay  
 Lipid concentrations were determined by the method adapted from the protocol of 
Rouser et. al. (145) (see Appendix 6-1 for phosphate assay protocol).  Initially 1 mL of 
membranes were pelleted and reacted with 5 μL of DNase for 1 hour at 37C to remove 
any background phosphate.  Membranes were pelleted at 50,000 xg for 2 hours at 4C 
and resuspended in 1 mL of 1X TAE.  The phosphate levels were normalized between all 
membrane samples by adjusting the final volume for resuspension after the final wash.  
 
Bicelle preparation 
 A 2x DMPC/DHPC bicelle solution (q=0.5 and 3% (w/w)) containing 38% CHS 
and 19% sphingomyelin was prepared by drying down DMPC, CHS and sphingomyelin 
out of chloroform.  Bicelles were rehydrated in 1XPBS and DHPC.  20 μL of 2 X bicelle 
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solutions was added to 20 μL of membranes and vortexed for 1 minute.  Samples were 
cleared by centrifugation at 50,000 xg for 1 hour at 25C.   
 
Reaction with maleimide probe 
 20 μL of protein in bicelles were reacted with 2 mM maleimide PEG of varying 
lengths (0.5, 1.2 and 5 kDa) for 5 minutes at 37C.  Reactions were quenched by the 
addition of 5 mM β-Mercaptoethanol (BME).  Samples were diluted to 100 μL with 1X 
PBS and 25 μL of 5X non-reducing SDS-page lading dye was added.  Samples were 
vortexed and boiled for 2 minutes.  A similar procedure was followed for the reaction 
with biotin maleimide.  
 
Purification on Nickel magnetic agarose beads 
 After reaction with the biotin maleimide, 500 μL of lysis buffer (50 mM 
phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole, 60 mM octyl-glucoside) was added 
to each sample.  Samples were vortexed and 15 μL of Nickel-NTA magnetic agarose 
beads (Qiagen, Germantown, MD)  were added and rotated overnight at room 
temperature.  After overnight incubation, samples were placed on a magnetic stand and 
the supernatant was removed.  The beads were washed twice with the lysis buffer 
containing 20 mM imidazole and 40 mM imidazole respectively.  Samples were eluted 
from the beads with 25 μL of elution buffer (same as the lysis buffer with 250 mM 
imidazole added).  SDS-page loading dye was added and samples were evaluated by 
western blot. 
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Western blot analysis of biotin maleimide 
  Biotin samples were run on a 0.75 mm 15% polyacrylamide gel and transferred 
to a PVDF membrane.  Blots were co-blocked in 0.5% casin in TBST with 1:2800 
avidin-AP.  After imaging of the biotin, blots were stripped by washing with water then 
100 mM NaOH and water again. After stripping blots were co-blocked in 0.5% powdered 
milk in TBST with 1:2800 myc-AP.  
 
Western Blot analysis of the maleimide PEG reaction 
 All PEG samples were run on a 0.75 mm 15% polyacrylamide gel and transferred 
to a PVDF membrane.  Blots were co-blocked with 0.5% (w/v) powdered milk and 
1:2000 Anti-myc antibody for 1 hour.  Blots were washed two times with 1X TBST.  
Blots were treated with 1:5000 anti-mouse antibody for 1 hour in 1X TBST.  
 
Imaging 
  Anti-avidin and anti-myc blots were visualized utilizing BioRad ChemiDoc 
XRS+.  Densitometry was performed utilizing Image Lab Software.  Percent labeling was 
determined by the addition of the two protein bands which is equal to the total protein.  
Then the density of the PEGylated band was divided by the protein total.  The 
percentages were normalized against the positive control (tyrosine 14) which is taken as 
100% labeling. 
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Results and Discussion 
Experimental design 
 To evaluate the accessibility of the caveolin-1 scaffolding domain 20 single 
cysteine constructs were generated.  Additionally, a construct with Y14 mutated to 
cysteine was generated as a positive control.  It has been shown that tyrosine 14 is 
phosphorylated in vivo and therefore it can be assumed that it is exposed to the aqueous 
environment and can represent 100% labeling (146).  A cysteine-less construct (full 
length caveolin-1 with the three native cysteines mutated) was used as a negative control.  
Additionally mutations to W115 and W128 were generated for comparison to previously 
published tryptophan fluorescence experiments.  With this method, the relative 
accessibility can be calculated based on the percent of biotin labeling compared to the 
total protein or the amount of PEGylated protein compared to the total protein.  
 
Phosphate assay to normalize protein concentration 
Because of variable expression between the different mutants, there is a need to 
standardize the concentrations.  In general, the ratio of lipid to protein seems to be 
constant between the different constructs and therefore, the phosphate concentration can 
be used to normalize the amount of protein and lipid between the different constructs 
(Figure 6-1).  This was true in the majority of the cysteine scanning mutants with the 
exception of four outliers that showed either significantly more protein (residues 99 and 
100) or significantly less (residues 85 and 92).  Even in the case of these extremes, the 
normalized intensity ratio did not exceed two-fold less protein or two-fold more protein.  
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Therefore, normalizing the phosphate levels in the E. coli membrane can be utilized, in 
the majority of cases to also normalize the protein concentration.  
 
Figure 6-1. Anti-myc western blot showing that the protein levels can be normalized 
utilizing the phosphate assay. All intensities were within error with the exception of 
residues 99 and 100 which showed significantly higher intensities, and residues 85 and 92 
which showed significantly lower intensities.  
 
Purification on magnetic Ni- NTA beads 
 Because the E coli membranes likely contain native proteins that contain cysteine 
residues, it is necessary to purify the caveolin-1 constructs to avoid background 
contamination.  By purifying the constructs after the reaction with the maleimide, the 
protein should be in its native conformation when it is reacted.  However, because of the 
large number of samples, there needs to be a high throughput purification technique 
employed.  Nickel affinity chromatography is a common technique that is used in protein 
purification.  The advantage of a poly-histidine tag is that it is small and non- perturbing 
which means that in most cases it does not need to be cleaved.  Ni-NTA magnetic beads 
allow for high through-put purification of poly-histidine tagged proteins.  The use of Ni-
NTA magnetic beads allowed for rapid purification of the cysteine containing constructs.  
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However, even with two washes at high imidazole concentrations (0, 25, 50, 75, 100, 
125, 150 ,175 and 200 mM), there is still a significant amount of background (Figure 6-
2). Additionally, at higher imidazole washes there is significant loss of the caveolin-1 
band (marked as 25 kDa in Figure 6-2).  This indicates that the reaction conditions are 
interfering with the nickel affinity reaction.  Even at high imidazole washes (200 mM), 
there are still several impurities that are observed.  
 
Figure 6-2. Representative biotin blot after imidazole washes of varying concentration. 
Y14C is used in this case as an example.  Lane 1, 0 mM imidazole, Lane 2, 25 mM 
imidazole, Lane 3 50 mM imidazole, Lane 4, 75 mM imidazole, Lane 5, 100 mM 
imidazole, lane 6, 125 mM imidazole, lane 7 150 mM imidazole, lane 8, 175 mM 
imidazole, and lane 9, 200 mM imidazole.   
 
Reaction with biotin maleimide 
 To assess the topology of the scaffolding domain of caveolin-1, the membrane 
fraction was isolated for all 22 cysteine containing constructs (20 constructs pertaining to 
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the scaffolding domain, Y14 as a positive control and wild-type as a negative control).  
The membrane fractions were then taken up into 2.3% q=0.5 bicelles that contained 
sphingomyelin and CHS which is a cholesterol derivative.  Because the scaffolding 
domain is postulated to interact with cholesterol and the high levels of cholesterol that are 
found in caveolae, CHS is incorporated to 38%.  After purification, there were significant 
differences in protein levels. For example, position 97 was not detected on either the 
biotin or myc_AP blot. Additionally, there is not a clear trend in accessibility (Figure 6-
3).  This highlights that the need to purify the protein adds significant error into the 
analysis.  
 
Figure 6-3. Relative labeling with biotin maleimide after nickel purification. 97 was not 
detected on either blot.  
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Reaction with maleimide PEG (5K) 
 The advantage of utilizing a maleimide PEG is that the protein does not have to 
be purified. Additionally, only one antibody is needed to probe the blots which can 
remove any error that is observed from stripping and re-probing.  However, when the 
cysteine mutants in the scaffolding domain are reacted with the 5K maleimide PEG there 
was no significant molecular weight shift.  This could indicate that the entire scaffolding 
domain is not exposed and is in fact buried in the plasma membrane.  However, there is 
also no reaction with Y14C which is known to be exposed in vivo (Figure 6-4).   
 
Figure 6-4. Representative western of Y14C and wild-type caveolin-1 reacted with 5 
kDa maleimide PEG. Lane 1 molecular weight ladder, lane 2, Y14C reacted with 0.2 mM 
5 kDa maleimide PEG, lane 3, Y14C reacted with 0.4 mM 5 kDa maleimide PEG, lane 4, 
Y14C reacted with 2 mM 5 kDa maleimide PEG, wild-type reacted with 2 mM 5 kDa 
maleimide PEG. 
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Additionally, when the 5 kDa maleimide PEG is reacted with a cysteine 
containing ubiquitin (which is a soluble protein) a molecular weight shift is seen but it is 
slowed significantly (reaction was only observed after 24 hours) (Figure 6-5).  This 
indicated that the 5 kDa maleimide PEG has extremely slow kinetics and that the 
presence of the membrane may introduce steric bulk that will disrupt the reaction of the 5 
kDa PEG with the protein.   
 
Figure 6-5. Reaction of ubiquitin_C2 with 5K maleimide PEG.  Lane 1, no PEG added. 
Lane 2, after reaction with maleimide PEG for 24 hours.  
 
Further, in the presence of 8M urea which is denaturing and should completely 
expose all the cysteine residues, there is still no significant molecular weight shift (Figure 
6-6).  All of this data supports that under the current reaction conditions the 5K 
maleimide PEG cannot react with the caveolin-1 scaffolding domain.  This could be due 
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to steric effects from the presence of the membrane or this could indicate that the 
caveolin-1 scaffolding domain is not  exposed when extracted from E. coli membranes.  
 
Figure 6-6. Representative western blot of the reaction of the cysteine mutants with 2 
mM 5 kDa maleimide PEG in the presence of 8 M urea. 
 
Reaction with smaller maleimide PEG derivatives   
In order to confirm that the lack of reaction with the cysteine residues is due to the 
size of the 5K PEG and not because the protein is not exposed, smaller maleimide PEG 
derivatives were reacted with the constructs (Figure 6-7).  Both the 0.5K PEG and 1.2K 
PEG showed a molecular weight shift when reacted with the cysteine residues in a subset 
of the scaffolding domain.  However, it does not appear that there is a clear trend in the 
ratios of labeling.  This could mean that the smaller maleimide PEG derivatives can (at 
123 
 
least to some degree) interact with cysteines in the membrane.  While there is significant 
evidence that the 5K maleimide PEG does not pass through membranes, less is known 
about the permeability of the smaller PEG derivatives into the membrane.  
 
Figure 6-7. Relative PEGylation of the caveolin-1scaffolding domain when reacted with 
1.2 kDa maleimide PEG. Error bars are based on three trials.  
 
Utilizing tryptophan residues to benchmark 1.2 K maleimide PEG reaction in the bilayer 
 Caveolin-1 has four tryptophan residues within the scaffolding and 
intramembrane domains (W85, W98, W115, and W128).  It has been shown previously 
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that the environment of the tryptophan residues (either exposed to the aqueous 
environment or buried in the membrane) can cause shifts in the fluorescence spectrum.  
Previous studies examining the exposure of the tryptophan residues of caveolin-1 in 
bicelles revealed that W85 and W128 were exposed, and W95 and W128 were buried in 
the membrane with W115 being the most buried (56).  Because of these well-established 
exposures, it is possible to make cysteine mutations at the four tryptophan residues and 
react with the 1.2 kDa PEG and compare the results to the previously published data.  
Figure 6-8 shows the labeling ratios of the four tryptophan residues when they are 
mutated to cysteine and reacted with the 1.2 kDa PEG. As observed previously W 85 
(which is the most exposed) shows the highest labeling ratio.  However the remaining 
three tryptophan residues (W98, W1115 and W128) show similar labeling ratios.  This 
indicates that the smaller PEG derivatives have some permeability into the membrane.  
The smaller PEG can therefore be used only to distinguish if a residue is exposed or 
buried and cannot establish subtle differences in residue depth within the bilayer. 
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Figure 6-8. Representative western of the four tryptophan mutants replaced with cysteine 
and reacted with 1.2K maleimide PEG.  The graph depicts the amount of labeling. The 
error bars are based on three trials.  
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Conclusion 
 Normally, the topology of a membrane spanning protein is easily determined by 
probing the accessibility of residues to a thiol reactive probe (143, 147).  Residues that 
are exposed to the aqueous environment can be labeled, while residues that are located in 
the bilayer are shielded and no reaction is observed.  Caveolin-1 presents a unique 
challenge because the protein does not actually span the bilayer.  Instead, it is thought to 
remain mostly in the inner leaflet and contain an intramembrane turn.  This presents 
unique challenges when attempting to determine the depth of the protein in the membrane 
as a large portion of the membrane domain (especially in the case of the scaffolding 
domain) may be interfacial.  Additionally, while the intramembrane domain shows a 
distinct stretch of hydrophobic residues, the sequence of the scaffolding domain is much 
more variable and does not show a clear trend in hydrophobicity.   
 The reaction with biotin maleimide has several disadvantages, the first that the 
protein has to be purified.  This can present technical challenges when examining a large 
sample set.  Secondly, it requires a stripping step which can introduce error.  One way to 
circumvent these challenges is to utilize maleimide PEG derivatives.  Because this 
reaction will cause a molecular weight shift, there is no need to purify the protein and it 
only requires a single antibody for detection.  Utilizing larger PEG derivatives will show 
the greatest molecular weight shift.  However, the reaction of the 5 kDa maleimide PEG 
with a ubiquitin construct containing a single cysteine, which is a soluble protein, is slow 
and requires almost 24 hours achieve complete labeling.  When the 5 kDa maleimide 
PEG is reacted with the cysteine mutations in the caveolin-1 scaffolding domain there is 
no significant reaction seen even after 24 hours or in the presence of denaturing agents 
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such as urea.  Smaller maleimide PEG derivatives do show reaction; however there is no 
real trend in reactivity.  This is most likely due to the ability of the smaller PEG 
maleimide to permeate the membrane (at least to a minor extent).   
 This chapter highlights the unique challenges that are presented when examining 
the topology of caveolin-1.  While the maleimide probes are able to give a qualitative 
result of “exposed” or “not exposed”, they are not able to elucidate the subtle differences 
in exposure that are necessary to establish the interfacial characteristic of caveolin-1.  
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Appendix 6-1. Phosphate assay protocol 
1. Dry down 5 to 10 μL of membranes into a film under N2.   
2. Add 330 μL of 70% percholric acid 
3. Heat samples to 220-240C for 45 minutes.   
4. Prepare standards by adding the appropriate amount of potassium phosphate to 
330 μL of 70% perchloric acid. 
5.   Allow lipid containing samples were cooled to room temperature and add 250 
μL of ascorbic acid  
6. Vortex to mix 
7. Add 250 μL of 2.5% ammonium molybdate  
8. Vortex to mix. 
9.   Bring samples and standards to a final volume of 2 mL with water.  
10.  Heat all samples and standards to 100C for 10 minutes.   
11. Cool to room temperature  
12. Read the absorbance at 800 nm. 
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Appendix 6-2. Sequences of cysteine scanning constructs. 
Construct Sequence 
D82C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFCGIWKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
G83C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDCIWKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
I84C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGCWKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
W85C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGICKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
K86C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWCASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
A87C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKCSFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
S88C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKACFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
F89C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASCTTFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
T90C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFCTFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
T91C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTCFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
F92C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTCTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
T93C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFCVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
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V94C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTCTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
T95C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVCKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
K96C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTCYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
Y97C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKCWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
W98C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYCFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
F99C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYWCYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
Y100C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYWFCRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
R101C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYWFYCLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
Y14C MSGGKYVDSEGHLCTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
WT MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
W115C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYWFYRLLSALFGIPMALICGIYFAIL
SFLHIWAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
W128C MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLND
DVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAIL
SFLHICAVVPSIKSFLIEIQSISRVYSIYVHTVSDPLFEAVGKIFSNVRINLQKEIEQKLI
SEEDLHHHHHH 
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Appendix 6-3. Structure of  Biotin maleimide  
 
Nα-(3-Maleimidylpropionyl)Biocytin 
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Chapter 7 Utilizing Homo-FRET to determine the oligomerization of membrane 
proteins 
Abstract  
Understanding the oligomeric state of membrane proteins is vital to 
comprehending the overall organization of the membrane. For example, it has been 
postulated that high molecular weight complexes, of which caveolin-1 is a primary 
component, form a scaffold that directly supports the highly-curved structure of caveolae.  
However, it can be difficult to uncover the exact oligomeric state of membrane proteins 
because of the need for plasma membrane mimetics that encompass the complexity that 
the protein experiences in vivo. To begin to understand the oligomeric state of membrane 
proteins, we have developed a homo-FRET assay that utilizes liposomes, which can 
incorporate physiological levels of cholesterol.  To benchmark our homo-FRET 
methodology, the oligomeric state of the transmembrane domain of Glycophorin A was 
examined which is known to form a stable dimer.  Measurement of steady state 
fluorescence anisotropy as a function of fluorophore labeling revealed that Glycophorin 
A behaves as a dimer in our system, and the addition of a mutation known to disrupt the 
dimerization showed a significant shift to a more monomeric state. Preliminary data on 
caveolin-1 suggests that the presence of physiologically-relevant levels of cholesterol had 
no effect on the minimum oligomeric state or change in the amount of monomer in the 
system. 
  
133 
 
Introduction 
The cellular membrane is a complex milieu of macromolecules of which 
membrane proteins constitute 50% by weight (148).  In many cases, membrane proteins 
are members of multi-protein complexes where they engage in homo- and/or hetero-
oligomerization (149, 150).  However, these homo- and hetero-oligomeric interactions 
can be difficult to characterize due to the complexity of the oligomers and the lipid 
environment.  Caveolae are an example of a domain that is unique to the bulk plasma 
membrane.  
Caveolae have been shown to be enriched in cholesterol at levels approximately 
twice that of the bulk plasma membrane (21). Therefore, caveolae can be classified as a 
“raft-like” domain (151). It has been shown that the depletion of cholesterol causes a 
dramatic change in both the number of caveolae on the cell surface and their morphology 
(19).  One of the major challenges when investigating how cholesterol effects membrane 
protein oligomerization is the inherent insolubility of cholesterol in most membrane 
mimetics. This is exacerbated by the need to incorporate large amounts (~38%) of 
cholesterol to accurately mimic the caveolae environment.  Consequently, it is necessary 
to utilize and develop methodologies that can evaluate the oligomeric state of caveolin-1 
under native-like conditions.  
One example of a membrane protein that is localized to these “raft like” domains 
and interacts with cholesterol is caveolin-1.  It has been postulated that there is a network 
of proteins (of which caveolin-1 is the most prevalent) that oligomerize at the caveolae 
surface that form a scaffold that helps to stabilize the highly curved nature of caveolae.  
However, the exact oligomeric state of caveolin-1 or the factors that contribute to the 
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formation of this network have not been established.  Caveolin-1 was first isolated via 
detergent extraction of cell plasma membranes (32, 33).  SDS-PAGE analysis of these 
detergent extracts revealed high molecular weight bands (200, 400, and 600 kD) that 
appeared to be predominantly the caveolin-1 protein, although these bands were found to 
be sensitive to the conditions in which the sample was loaded (43, 124). This observation 
established the postulation that caveolin-1 homo-oligomerizes. Later studies concluded 
that caveolin-1 forms high-order aggregates in a stepwise fashion, starting with 14-15 
caveolin-1 monomers (identified as the 8S complex) which then combine to form  larger 
oligomeric complexes (identified as 70S and 80S complexes) (7, 24, 65). However, all of 
these complexes have been shown to be highly sensitive to the sample conditions 
employed (i.e. detergent used), and therefore, it is unclear if these complexes fully 
recapitulate the caveolin-1-rich complexes observed in vivo.  Because of the complex 
nature of caveolin-1 oligomerization, a new method to determine not only the size of the 
oligomeric complex, but also the effect of the environment (i.e. cholesterol) must be 
established.  
In the current study, an in vitro homo-FRET methodology was developed  to 
probe the oligomeric state of membrane proteins in liposomes (see Chapter 1 for homo-
FRET introduction).  First, the methodology was validated using the transmembrane 
domain of glycophorin A which is known to form a stable homodimer.  It is also shown 
that this method is also able to determine changes in oligomeric state due to point 
mutations using known mutated constructs of glycophrin A that are shown to disrupt 
dimerization.  This method was then used to determine the effect of physiologically 
relevant levels of cholesterol on the homo-oligomeric state of caveolin-1 in lipid vesicles.  
135 
 
Materials and Methods 
Design of Construct.  
  M-Cherry_Caveolin1_MYC_His was expressed in Escherichia coli BL21(DE3) 
cells. The C-terminal MYC tag is known to preserve properties of native caveolin. (139) 
Caveolin-1 contains three native cysteine sites that are known to be palmitoylated in vivo. 
However, this palmitoylation has been previously shown to have no influence on the 
trafficking to the membrane or the formation of caveolae. (31) Therefore, the mutation of 
the three cysteine residues to serine has no effect on innate caveolin-1 function.  The 
mCherry_Caveolin1_myc-H6_Y72F construct was generated by Quikchange 
mutagenesis and sequencing was confirmed. The mCherry_Glycophrin A_61-101_myc 
gene was purchased from genscript and cloned into pet24a. Two monomeric mutant 
constructs were generated by changing glycine 83 to an isoleucine and alanine which 
have been shown to disrupt dimerization.  A “free” mCherry construct was generated by 
inserting a stop codon into a H6_mCherry_ caveolin-2 construct.  
 
Cell Culture  
An overnight culture was used to inoculate 1L of ZYM-5052 media. Cells were 
grown for 24 hours at 25°C. Cells were harvested at 8200 xg for 15 minutes. 1L cell 
pellets were washed with 200 mL of 0.9% saline and stored at -80C until ready for use. 
Protein pellets were thawed and resuspended in 40 mL of 1X TAE with 1 mg/ml of 
lysozyme and stirred on ice for 15 minutes. Cells were lysed by sonication using a 
Branson sonifier 450 (duty cycle 1, power 10) in 10 minute intervals for 30 minutes total 
(10 minutes on, 5 minutes off).  The lysate was cleared for 30 minutes at 30,000 xg. The 
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supernatant was centrifuged at 130,000 xg for 15 minutes to pellet the membrane 
fraction.  Membranes were resuspended in 2.5 mL of 1 X PBS with 30% (w/v) sucrose 
and stored at -20C for future analysis.  H6_mCherry was prepared similarly, however 1L 
cell pellets were resuspended in 1 X PBS with 30% (w/v) sucrose containing 1 mg/ml 
lysozyme and lysed using sonication as described above. The lysate was cleared for 1 
hour at 4C. The pellet was discarded and the supernatant stored at -20C.  
 
Ni-NTA Purification 
 Caveolin-1 membranes were solubilized in 50 mM phosphate pH 8.0, 300 mM 
NaCl, 10 mM imidazole and 2% Empigen BB.  Samples were cleared for 30 minutes at 
20,000 xg.  Samples were loaded onto a Ni-NTA column.  The column was washed with 
10 column volumes of 150 mM octylglucoside, 10 mM Tris pH 8.0 and 154 mM NaCl.  
Protein was eluted in 1 mL fractions with 150 mM octylglucoside, 10 mM Tris pH 8.0, 
154 mM NaCl and 250 mM imidazole.  The most concentrated samples were pooled and 
concentrated 10 fold.  
 
Quantitation of light and dark constructs 
 After nickel purification, the amount of protein was determined using a micro 
BCA assay.  The results from the BCA were confirmed by the examining the absorbance 
of the “light” sample at 587 nm.  Once the concentration was accurately determined both 
the light and dark sample were diluted to 15 μM with 150 mM octylglucoside, 10 mM 
tris pH 8.0, and 154 mM salt.  
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Reconstitution of membrane proteins into vesicles 
Vesicles were prepared following protocol outlined by Jiskoot et al. (152) Sets of 
seven phosphatidylcholine vesicles were made with increasing molar ratios of fluorescent 
label (0.1, 0.25, 0.4, 0.55, 0.7, 0.85, 1 molar ratio of fluorophore). Membrane fraction 
was solubilized using 150 mM octylglucoside, 0.9% NaCl, 10 mM Tris pH 7.4.  Egg PC 
was solubilized in 150 μL of the same buffer for a final concentration of 10 mM.  For 
cholesterol containing samples a mixture Egg PC and cholesterol were dried out of 
chloroform and resuspended in 150 μL of octylglucoside for a final concentration of 38% 
cholesterol.  To ensure the incorporation of the lipids into the vesicles, lipids were 
quantified by phosphate assay as described by Rouser, et al. (145) and cholesterol content 
determined by Cayman Chemical Cholesterol Fluorometric Assay Kit according to 
manufacturer’s instructions. It is important to note that in order to achieve cholesterol 
incorporation it is necessary to elevate the temperature to 40C during vesicle 
preparation. Significantly less cholesterol is incorporated at lower temperatures.  
Dilution was performed using Dionex P580 HPLC pump, by adding the 
appropriate amount of dilution buffer(154 mM NaCl, 10 mM Tris pH 7.4 with 250 mM 
sucrose) at a constant rate to achieve a final octylglucoside concentration of 15 mM (15 
mL in the case of caveolin-1 samples and 3 mL for all other samples). Following dilution, 
samples were concentrated to <150 μL by ultrafiltration. Samples were subsequently 
washed by adding half of the initial volume of dilution buffer and concentrated to <150 
μL and then dilution buffer was added for a final volume of 300 μL. Formation of 
vesicles was confirmed by Dynamic Light Scattering ALV/CGS-3 Compact Goniometer 
System.  
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Fluorescence Anisotropy.  
Steady state anisotropy was measured using Horiba Scientific Fluorolog-3 at 
25°C. Data was fit using correlation function for the determination of anisotropy in a 
population of oligomers, as outlined by Yeow et al., (93) with Igor Pro 6.3a (equation 7-
1).  
Equation 7-1 
r(f,N) = rm(x+(1-x)(1-f)^(N-1)) 
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Results and Discussion   
Creation of non-fluorescent mCherry 
 mCherry is an ideal fluorophore for homo-FRET because of its small Stokes shift 
(Forster distance of 5.10 nm) (153).  However, for oligomeric analysis, one needs to vary 
the ratio of labeled to unlabeled subunits.  In vivo, this is done by photobleaching the 
fluorophore to various extents to achieve the desired ratios (92, 154, 155).  Unfortunately, 
this approach is not conducive to in vitro analysis, and certain fluorophores, such as 
mCherry, are highly resistant to photobleaching (156).  In this study, the unlabeled 
sample was generated by making a point mutation to the mCherry protein.  Mutation of 
tyrosine 72 to phenylalanine interferes with the generation of the chromophore, and 
hence renders mCherry non-fluorescent (Figure 7-1).   
 
Figure 7-1. Comparison of the fluorescence intensity between wild-type H6_mCherry 
(light) and H6_mCherry_Y72F (dark).  The dashed line represents the fluorescence of the 
dark at 587 nm and the solid black line represents the wild-type at the same wavelength.  
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However, to insure that this mutation is not altering the overall fold of the 
mCherry protein, circular dichroism analysis was undertaken.  Figure 7-2 shows that both 
the wild-type and mutant mCherry have very similar far UV CD spectra which shows that 
the overall β-barrel fold of the protein remains intact. This indicates that the structural 
integrity of mCherry is not disrupted by the introduction of the point mutation.  In 
addition, the CD spectra in Figure 7-2 is in agreement with previously published spectra 
of mCherry (157). Therefore, this methodology is suitable to obtain the various ratios of 
labeled to unlabeled protein needed for homo-FRET analysis. 
 
Figure 7-2. CD spectrum comparing H6-mCherry ( black line) and H6_mCherry_Y72F 
(blue line). The signature minimum at 218 nm is indicative of a β-sheet structure. 
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Oligomeric behavior of mCherry itself in the absence and presence of liposomes 
 In the methodology described herein, the oligomeric state of a membrane protein 
is determined by creating a fusion construct with mCherry which serves as the homo-
FRET reporter.  However, before undertaking any inquisition into the oligomeric 
behavior, it is important to characterize first the behavior of mCherry itself in the 
presence and absence of liposomes.  mCherry is a construct that has been engineered to 
have monomeric behavior, but it may behave differently in the presence of liposomes 
(158).  First, a homo-FRET analysis was done of mCherry alone in buffer (Figure 7-3).  
When the data was fit to Equation 7-1, two quantities were determined, x which is the 
fraction of monomer and N which is the minimum oligomeric state. 
 
Figure 7-3. Anisotropy fit for H6_mCherry in buffer. Error bars are based on the average 
of three trials, however they are too small to be seen on the graph.  
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Clearly, the overwhelming majority of mCherry is monomeric as the fraction 
monomer, x, is 0.96 + 0.00087.  The other 0.04 fraction has a minimum oligomeric state 
of 2.05 + 0.051.  Therefore, although the engineered mCherry is largely monomeric there 
is a small oligomeric population (i.e. dimer).  Therefore if results using an actual fusion 
protein construct show x values of 0.96 or higher, the determined N could be due to the 
mCherry itself and not the protein of interest.  Therefore, conclusions should not be 
drawn from x values that are greater than 0.96.  Next, a second homo-FRET analysis was 
done, this time in the presence of liposomes (Figure 7-4).  Fortunately, no difference was 
observed when liposomes are added, x remains 0.96 + 0.0026 and N is 2.05 + 0.15.  
Therefore, the presence of a lipid bilayer does not influence the behavior of mCherry.    
 
Figure 7-4. Steady state anisotropy fit for H6_mCherry in the presence of liposomes.  
Error bars are based on the average of three trials. 
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Validation of method with the transmembrane domain of Glycophorin A  
The transmembrane domain of glycophorin A (GlyA) is a known stable 
homodimer, and has been extensively characterized (159, 160, 161).  Additionally, the 
dimerization of Glycophorin A has been previously analyzed in vesicles prepared in 
several different ways and showed that there were no significant changes in the 
dimerization free energies (162).  Therefore, it is an ideal membrane protein in which to 
benchmark this method.  
 To validate the homo-FRET method wild type GlyA was incorporated into 
liposomes and the steady state at varying molar ratios of “light” to dark was determined 
(Figure 7-5).  The results were fit using equation7-1 and the minimum oligomeric state 
(N) was determined to be 2.02 + 0.065 and the percent of monomer was determined to be 
0.50 + 0.009. This indicates that the major species is confirmed to be a dimer which is the 
expected oligomeric state of GlyA.   
 
Figure 7-5 Anisotropy fit of wild type GlyA in the presence of liposomes. Error bars 
represent the average of three trials.  
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Detection of changes in oligomeric state due to point mutations 
 To evaluate if homo-FRET can determine changes in the oligomeric state based 
on the presence of point mutations, two separate monomeric GlyA constructs were 
designed (G83I and G83A).  Glycine 83 has been identified as a critical residue to 
maintain the GlyA dimer.  It is postulated to be part of the critical dimerization motif 
(GXXXG) (163).  Through mutational scanning experiments it was shown that the 
introduction of any other amino acid at position 83, disrupts the dimerization but the 
alanine and isoleucine are particularly disruptive (164, 165, 166).  Both G83A and G83I 
showed a change in percent of monomer when compared to the wild-type protein.  
However, there is also a change in the minimum oligomeric state when compared to the 
wild-type (Table7-1).  This can be attributed to the presence of a high order inactive 
tetramer that has been previously reported in analytical ultra-centrifugation experiments 
of the monomer mutants in micelles (167).  Additionally, all previous studies on these 
monomeric constructs have been performed either in vivo or on purified protein.  It is 
unclear how utilizing the monomeric constructs extracted from membranes will affect the 
overall oligomeric state.  But these results prove that utilizing homo-FRET, it is possible 
to evaluate changes in the oligomeric state from the introduction of point mutations.  
However, these results cannot be viewed in an absolute manner but rather used as a 
comparison with the wild-type.  
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Construct N (minimum oligomeric state) X (percent monomer) 
WT _GLYA 2.02 + 0.06 0.50 + 0.009 
G83A_GlyA 2.49 + 0.23 0.73 + 0.014 
G83I_GlyA 2.35 + 0.12 0.72 + 0.001 
 
Table 7-1. Comparison of the N and x values calculated for the wild-type_GlyA and the 
two mutant constructs.  
 
Incorporation of cholesterol into liposomes 
Because of the high percentage of cholesterol in caveolae, it was necessary to 
ensure that cholesterol was incorporated into the vesicles at relevant amounts.  Vesicles 
were prepared according to Jiskoot et al with a projected concentration of cholesterol of 
38% (152).  To determine the percent of cholesterol incorporation, two assays were 
utilized: a cholesterol assay and a phosphate assay.  In the lipid vesicle preparation the 
phosphate concentration was determined to be 5.8 mM + 0.72 while the cholesterol 
concentration was determined to be 3.75 mM + 0.45. Therefore the percentage of 
cholesterol was 39.3% + 4.2. Therefore, the cholesterol levels within the lipid vesicles is 
relevant to the levels of cholesterol in caveolae which have been shown to be between 
35-38% (21).  
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Analysis of the oligomeric state of caveolin-1 in the presence of cholesterol 
 To evaluate the oligomeric state of caveolin-1 in the presence liposomes, varying 
ratios of light and dark mCherry_caveolin-1 were incorporated into liposomes.  
Previously, the oligomeric state of caveolin-1 was evaluated in micelles and bicelles 
using analytical ultracentrifugation. These studies revealed that the protein was 
monomeric (44).  However, it is not possible to utilize liposomes in the AUC and 
therefore another technique such as homo-FRET must be utilized to compare how 
changing the bilayer mimetic affects the oligomeric behavior.  When the anisotropy data 
for caveolin-1 was fit to equation 7-1, it was found that the majority of the protein is 
monomeric (Figure 7-6).  However, the minimum oligomeric state was determined to be 
4.  This is the first in vitro analysis to show a high ordered species of caveolin-1.  
Importantly, there is no significant change in the oligomeric state of caveolin-1 in the 
presence of cholesterol.  By utilizing homo-FRET not only can the oligomeric state of 
caveolin-1 be investigated but also changes in the environment and how the introduction 
of point mutations affect the overall oligomeric state can be probed.  It should be noted 
that the homo-FRET studies of caveolin-1 are on-going and need further validation to 
determine the true oligomeric state. However, these are promising initial results.  
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Figure 7-7. Comparison of A) the degree of oligomerization and B) the % monomer of 
caveolin-1 in the presence and absence of cholesterol (data collected by Sophia Miotto).  
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Conclusions 
This chapter presents a novel homo-FRET assay to determine the oligomeric state 
of membrane proteins in liposomes in the presence of cholesterol.  This method can 
detect the overall oligomeric state of membrane proteins (as seen in the case of GlyA) 
and also evaluate changes in oligomerization due to mutations.  In this way, this 
technique can be used in a comparative manner.  Preliminary studies on caveolin-1 
indicate that the presence of cholesterol does not affect the oligomeric state of caveolin-1.  
Therefore, the high levels of cholesterol found in caveolae are not required for the 
formation of the network of oligomers thought to stabilize caveolae.  Additionally, 
previous in vitro assays to determine the oligomeric state of caveolin-1 have shown that it 
is monomeric.  This is the first in vitro analysis that suggests a higher order oligomeric 
state of caveolin-1 in vitro.  However, further studies need to be conducted to establish 
the nature of this oligomeric state. Overall, homo-FRET utilizing mCherry as a 
fluorescent probe is an exciting new way to probe the oligomeric state of membrane 
proteins in native like bilayers.   
  
149 
 
Chapter 8 PFOA as a powerful tool to solubilize inclusion bodies  
Abstract 
The purification of membrane proteins can be challenging due to their low 
solubility in conventional detergents and/or chaotropic solutions.   The introduction of 
fusion systems that promote the formation of inclusion bodies has facilitated the over-
expression of membrane proteins.  The protocol presented, describes the use of 
perfluorooctanoic acid (PFOA) as an aid in the purification of highly hydrophobic 
membrane proteins expressed as inclusion bodies. The advantage of utilizing PFOA is 
threefold: first, PFOA is able to reliably solubilize inclusion bodies, second, PFOA is 
compatible with nickel affinity chromatography, and third, PFOA can be efficiently 
dialyzed away to produce a detergent free sample.  To demonstrate the utility of 
employing PFOA, a segment of the extremely hydrophobic membrane protein caveolin-1 
was expressed and purified. 
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Introduction  
 Membrane proteins are major players in cellular biology.  They are responsible 
for a plethora of cellular functions such as signal transduction and transport (168).  
Additionally, a large number of drug targets have been identified as membrane proteins, 
indicating that these proteins are heavily involved in normal cell function (169).  
However, the purification and analysis of these membrane proteins can be challenging 
because of their highly hydrophobic characteristics and strong propensity to aggregate 
(170).  In addition, recombinant expression of membrane proteins usually results in low 
yields due to stresses put on the host membrane which results in toxicity. However, the 
over-expression of membrane proteins into inclusion bodies has emerged as a powerful 
tool to achieve high levels of protein in E. coli cells by eliminating the toxicity issues 
mentioned above which limit protein production (95).   
Inclusion bodies can be isolated through a series of wash treatments that separate 
them from the soluble and membrane components of the host cell. While this insolubility 
is an attractive feature in aiding the isolation of the protein, it can be an obstacle when it 
comes to solubilizing the protein.  Typically strong chaotropic solutions such as 8 M urea 
or 6 M guanadinium hydrochloride are utilized.  However, for highly hydrophobic 
membrane proteins, these solutions are often not powerful enough to completely dissolve 
the inclusion bodies.  Alternatively, strong detergents such as sodium dodecyl sulfate are 
attractive, but many of these detergents are not compatible with widely used purification 
techniques such as nickel affinity chromatography.  Furthermore, it is often difficult, if 
not impossible, to remove these harsh detergents from the sample, which can be 
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problematic, as it is often desirable to acquire experimental results in the presence of a 
native-like detergent and lipid systems.  
 Perfluorooctanoic acid (PFOA) is a powerful detergent that has been shown to 
have the ability to solubilize membrane proteins (Figure 8-1) (171).  In this report, the 
utility of PFOA is extended by showing that it can dissolve highly hydrophobic 
membrane proteins expressed as inclusion bodies.  Furthermore, it is compatible with 
nickel affinity chromatography, and can be easily removed by dialysis, providing a 
detergent-free precipitate that can then be solubilized in a detergent or lipid system of 
choice.  To demonstrate the usefulness of PFOA, we detail the purification of the integral 
membrane protein caveolin-1 from inclusion bodies.  Caveolin-1 is the preeminent 
protein in membrane invaginations called caveolae, which have been shown to be crucial 
for caveolae formation, signal transduction, mechano-protection, and endocytosis; 
however studies of this protein have been hindered by its extremely hydrophobic 
character (35, 44, 113, 121). Because of this, caveolin-1 is an ideal candidate to 
demonstrate the utility of PFOA.  
 
 
Figure 8-1. Structure of perfluorooctanoic acid (PFOA) (172). 
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Materials and methods 
Protein expression 
 H9_TrpLE_caveolin-1_62-178 was cloned into the pET-24a vector, and 
transformed into BL21(DE3) cells.  1 mL of an overnight culture (20 hours) in MDG 
media was used to inoculate 1 L of ZYM-5052 media (105).  The culture was shaken at 
250 rpm on an orbital shaker at 37°C for 12-14 hours.  Cells were harvested at 8200 x g 
for 15 min at 4°C, resuspended in 0.9% (w/v) NaCl, and re-centrifuged at 5000 x g for 30 
min at 4°C.  Pellets were stored at -80°C until needed. 
 
Protein purification 
 1 L cell pellets were resuspended in 200 mL of a buffer containing 20% (w/v) 
sucrose, 10 mM Tris pH 8.0, 1 mM EDTA and 50 mM BME. Cells were lysed by 
sonication in a Branson Sonifier 450 for 15 minutes (power level 40 and duty cycle 5) 
with stirring at 4°C.  Next, the lysis was centrifuged for 2 hours at 27,500 x g at 4°C.  
The supernatant was removed, and the pellet was resuspended in 200 mL of a buffer 
containing 1% (v/v) Triton X-100, 10 mM Tris pH 8.0 followed by sonication for 15 
minutes with stirring at 4°C. The mixture was centrifuged at 27,500 x g for 1 hour at 4°C.  
The supernatant was discarded, and the remaining pellet contained the isolated inclusion 
bodies. 
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Solubilization of inclusion bodies 
 Isolated inclusion bodies were dissolved in 40 mL of 8% (w/v) PFOA, 25 mM 
phosphate pH 8.0 and homogenized using a dounce homogenizer. The solution was then 
centrifuged at 50,000 x g for 30 min at 22°C.  The supernatant contained the solubilized 
inclusion bodies. 
 
Ni-NTA purification 
 After solubilization into 8% (w/v) PFOA, the supernatant was filtered through a 
0.2 μm filter and loaded onto a column containing 20 mL of Ni sepharose 6 resin.  The 
column was washed with approximately 5 column volumes of 1% (w/v) PFOA, 25 mM 
phosphate pH 8.0, or until the absorbance at 280 nm was steady, to remove any unbound 
protein.  Samples were eluted in the presence of 1% (w/v) PFOA, 25 mM phosphate pH 
8.0, 250 mM imidazole. 
 
Dialysis 
 The most concentrated column fractions were pooled, and placed in 10,000 
MWCO dialysis tubing.  Samples were dialyzed against 20 L of 50 mM ammonium 
sulfate for 24 hours at room temperature with stirring.  Precipitated protein was isolated 
by centrifugation at 4000 x g for 30 min at 22°C. The pellet contained the purified 
precipitated protein. 
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Results and Discussion  
Inclusion body production and solubilization 
 Inclusion bodies have emerged as a powerful tool to obtain high levels of 
membrane proteins expressed in E. coli cells.  One of the challenges of membrane protein 
expression, especially of a non-native membrane proteins, is that the over-expressed 
protein can crowd the membrane and become toxic to the bacterial cell (173).  This leads 
to low protein expression that can make protein isolation very challenging due to the high 
background of endogenous host proteins. However, the fusion of a membrane protein to 
particular proteins will cause the protein of interest to be rapidly expressed in an unfolded 
state, and incorporated into insoluble cytoplasmic aggregates (i.e. inclusion bodies).  One 
of the common proteins utilized to promote inclusion body formation is trp leader (trpLE) 
which has been shown to result in significantly enhanced membrane protein expression 
(174). Advantageously, the properties of these aggregates can then be exploited to extract 
the protein of interest.  First, the cells are lysed in a buffer containing sucrose which 
removes soluble cellular components.  After centrifugation, this leaves a pellet that 
contains only the inclusion bodies and other hydrophobic membrane components. These 
hydrophobic membrane components can be removed via a second lysis step that utilizes a 
buffer containing a mild detergent (in this case Triton X-100).  Since Triton X-100 will 
not solubilize the inclusion bodies, after centrifugation, the majority of the pellet contains 
inclusion bodies. 
 Normally, once the inclusion bodies have been isolated from the whole cell 
milieu, they are solubilized in either 8 M urea or 6 M guanidinium hydrochloride. 
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However, in the case of highly insoluble transmembrane domains, even solutions of these 
strong chaotropic agents cannot effectively solubilize the inclusion bodies. For example, 
when the membrane interacting domain of caveolin-1 (residues 62-178, GRAVY score 
0.659) is expressed with the fusion protein trp leader, the inclusion body pellet is not 
soluble in either 8 M urea or 6 M guanidinium hydrochloride (data not shown) (175). For 
this reason, the conventional methodology for processing inclusion bodies was not 
applicable.   However, it was determined that a solution of 8% (w/v) PFOA can 
efficiently and rapidly solubilize inclusion bodies (Figure8-2).  Additionally, in some 
cases, the addition of 1% (w/v) PFOA to a solution containing 8 M urea can significantly 
enhance the ability of 8 M urea to solubilize hydrophobic inclusion bodies, thereby 
decreasing the need for a very high detergent concentration.  
 
 
Figure 8-2. SDS-PAGE analysis of caveolin-1 (62-178) inclusion bodies dissolved in 8% 
(w/v) PFOA. Lane 1, Molecular weight ladder; lane 2, caveolin-1 in PFOA buffer pre-
centrifugation; lane 3, caveolin-1 in PFOA buffer post-centrifugation (50,000 x g) (172).  
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The pKa of PFOA has been reported to be between 2.8 and 3. However, there is a 
study that has determined the pKa to be substantially lower, approximately -0.5 (176, 
177).  Whichever value is most representative, the low pKa of PFOA is an advantage 
because it will not interfere with typical buffering  agents in the 4 to 12 range. It is also 
important to note that PFOA can form precipitates with potassium counterions, therefore, 
buffer conditions are limited to the use of sodium or ammonium counter ions.   
Additionally, it should be noted that due to the exclusionary fluorous nature of PFOA, it 
is incompatible with many other common detergents, such as Empigen BB, so caution 
should be taken when working with other detergents.   Similarly, guanadinium 
hydrochloride is not compatible with PFOA as it forms a precipitate.  
Purification 
 Nickel purification has arisen as a key tool for the purification of proteins.  The 
hexa-histidine tag imparts specificity for binding to the nickel-bound nitrilotriacetic acid 
resin, but due to its small size it generally will not perturb the  protein structure or its 
function (178). Most of the time, this eliminates the need to do additional cleavage steps 
to remove the affinity tag. The purification of membrane proteins using nickel affinity 
can be challenging.  Membrane proteins need detergents for solubility, and not all 
detergents are compatible with the resin chemistry. Many milder detergents that are 
compatible with nickel affinity chromatography are not sufficient to keep the highly 
insoluble membrane proteins in solution much less solubilize them from an inclusion 
body state. In contrast, several stronger detergents (e.g. SDS) are able to solubilize 
inclusion bodies and keep the protein in solution, but interfere with the binding affinity of 
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the column. This makes PFOA an attractive choice as it is able to both solubilize 
membrane proteins, and is compatible with the nickel affinity column chemistry.  In this 
case, the nickel chromatography trace of a nona-histidine tagged Trp leader fusion of 
caveolin-1 residues 62-178 is presented as an example of an insoluble membrane protein 
that can be purified using nickel affinity chromatography with PFOA buffers (Figure 8-
3a).  Although 8% (w/v) is needed to initially solubilize the inclusion bodies, the column 
can be run in 1% (w/v) PFOA which is sufficient to keep the protein in solution.  In 
addition, the high ionic strength of the PFOA detergent mediates any ion exchange 
effects with the resin so the addition of NaCl to the buffer (typically 300 - 500 mM) is not 
needed.  Imidazole can be added to the wash to enhance the purity of the finally product 
(0 mM - 40 mM), but the maximum tolerated level before there is significant protein loss 
must be determined for each protein individually. However, for caveolin-1 very high 
purities have been obtained without using imidazole in the wash step (Figure8-3b).  
Elution is accomplished using a 1% (w/v) PFOA solution containing 250 mM imidazole.  
The elution can also be done with a 1% (w/v) PFOA solution at a pH of 4.5.  However it 
is important to keep in mind that the solubility of PFOA decreases dramatically below a 
pH of 4.0.    
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Figure 8-3. A) Representative chromatogram of the nickel affinity column purification of 
caveolin-1 (62-178). B) SDS-PAGE analysis of nickel purified caveolin-1 in PFOA. Lane 
1, molecular weight ladder; lane 2, caveolin-1 (62-178) after elution (172).  
 
Dialysis 
 One of the major challenges of membrane protein purification is that often times, 
the detergents that are necessary for purification are not desirable for the downstream 
characterization of the protein. For example, PFOA may be used for purification, but the 
final experiments are desired to be done in phospholipid vesicles.  Also, there are cases 
where even the residual presence of even a few detergent molecules can cause erroneous 
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results (179).  One common method for the removal of detergents is dialysis. However,  
many detergents that are commonly used in membrane protein expression have very low 
CMC values making them difficult if not impossible to remove using this method. This 
again highlights the need for a detergent that meets three fundamental requirements: 
protein solubilization, compatibility with purification techniques and the ability to be 
readily removed.  PFOA has been shown to be removed by slow dialysis over time (171).  
This is due to the relatively high CMC of PFOA (reported as 13-30 mM, depending on 
the buffer system (171)). When the protein is loaded onto the nickel column, it can be 
washed into 1% (w/v) PFOA. This is advantageous as the 1% (w/v) PFOA can be more 
readily dialyzed than an  8% (w/v) solution. The dialysis of a 50 mL solution against 20 L 
of water at room temperature is sufficient to cause 100% precipitation of the protein 
(Figure 8-4).  After precipitation, the protein is recovered by gentle centrifugation (4000 
x g).   Next, the precipitated protein can be washed several times to remove all traces of 
PFOA.  Importantly the addition of 50 mM ammonium sulfate to the dialysis buffer 
significantly enhances the rate of protein precipitation. This precipitate is extremely easy 
to redissolve in whatever downstream detergents and/or lipids that are desired. 
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Figure 8-4. SDS-PAGE analysis of caveolin-1 after precipitation. Lane 1, molecular 
weight ladder; lane 2, caveolin-1 (62-178) after precipitation before centrifugation, lane 
3, supernatant after centrifugation of precipitated caveolin-1 (172).  
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Conclusions 
 Obtaining sufficient amounts of insoluble membrane proteins at high levels is 
crucial to the understanding of protein structure and function through biophysical 
characterization.  However, there are several challenges to obtaining high levels of 
purified membrane proteins, most notably the need for a detergent system that is 
compatible with both purification techniques and downstream characterization. In the 
procedure described herein, we demonstrate that PFOA has a threefold advantage when 
applied to the purification of membrane proteins.  First, it is able to efficiently dissolve 
inclusion bodies.  Second, it is compatible with Ni-NTA purification. Finally, it can be 
easily removed through dialysis, which produces a detergent free sample that can be 
carried through for additional purification such as cleavage of the fusion protein or 
incorporation into other membrane mimics. 
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